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XIII BALTIC CONGRESS IN  LABORATORY MEDICINE
Dear Colleagues,
On behalf of the Baltic Association of Labo-
ratory Medicine (BALM) and the Organizing 
Committee, I would like to express my great 
pleasure inviting you to participate in the 
XIII Baltic Congress in Laboratory Medicine. 
This important event will be held in Tartu, 
Estonia, on May 12–14, 2016 at the Dorpat 
Conference Centre. 
The Congress will be held under the 
auspices of the International Federation of 
Clinical Chemistry and Laboratory Medicine 
( IFCC) and the European Federation of 
Clinical Chemistry and Laboratory Medicine 
(EFLM) and with the generous support of 
the IFCC Visiting Lecturer Programme.
 e BALM Congress Tartu 2016 is going 
to be an invigorative event reﬂ ecting the 
state of art and directions of laboratory 
medicine at the time of a changing health 
care environment.  e Congress will focus on 
topics of how laboratory medicine can help 
clinicians to treat patients in a better way. 
The Scientific Committee has worked 
hard to present a challenging scientific 
programme in the form of plenary lectures, 
scientific sessions, workshops and a poster 
session. Baltic, Nordic and international 
speakers will bring along their best knowl-
edge for sharing their ideas. Both young and 
experienced colleagues will present posters 
on their research findings. Partners from 
the diagnostic industry will introduce new 
developments and ideas at a commercial 
exhibition and in presentations.
Welcome to the XIII Baltic Congress 
in Laboratory Medicine!
The BALM Congress Tartu 2016 will 
offer an excellent opportunity to meet 
colleagues, to gather knowledge, and to 
share information. We hope that it will 
also help to strengthen cooperation and 
communication between Baltic and inter-
national colleagues.   
Tartu, called also the Athens of the River 
Emajõgi, is a beautiful university town, and 
a modern city with rich historical heritage 
and culture. A walk in the Old Town and in 
the Town Hall Square, as well as the vibrant 
spring atmosphere of this student town 
with its sightseeing sites, like the Ahhaa 
Science Centre, the Vanemuine theatre and 
the university buildings, will undoubtedly 
be an enjoyable experience.
Welcome to Tartu 2016!
Dr Karel Tomberg
President of the Congress 
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12.30–13.00 Quality system for GPs; Norwegian example Sverre Sandberg, Norway
13.00–13.30 How is EFLM WG-PRE contributing to the improvement of 
preanalytical phase quality in Europe
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13.30–14.00 Critical risk results in Europe Eva Ajzner, Hungary
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The mission statement of IFCC is to be the leading 
organisation in the f ield of Laboratory Medicine 
worldwide. Its membership ref lects this aim, 90 full 
member national learned societies and six affiliate 
member societies that are most strongly affiliated 
to six Regional federations as well as 46 corporate 
institutions.
The organisation of IFCC is effected through its 
Council, comprising representatives of all National 
Societies and its Executive, membership of which is 
elected triennially. Council and Executive oversee 
three operat ional Div isions, the Scienti f ic Div i-
sion (SD), the Education and Management Division 
(EMD) and the Communications and Publications 
Divisions (CPD), specialist committees and special 
task forces. Each Division has its own committees 
and working groups. Members of the committees 
and working groups are nominated by National Soci-
eties and Corporate Members; this provides many 
opportunities for individuals to contribute to the 
work of IFCC. National Societies; also individuals can 
take advantage of IFCC special projects such as the 
Visiting Lecturer Programme (VLP) the Professional 
Exchange Programme (PEP) the Speakers’ Bureau and 
the Register of Experts.
In recent years distance learning has become a key 
initiative of IFCC; the EMD Committee on Distance 
Learning (C-DL) and the CPD Committee on the Internet 
and e-Learning (C-IeL) have been collaborating to develop 
the IFCC eAcademy, which will produce high quality 
educational modules available to its membership. The 
eAcademy will provide a resource for individuals in 
their training and CPD requirements as well as for 
those in the planning and organisation of educational 
programmes.
 e eAcademy is a Learning Management System 
which uses a curriculum based approach to catalogue 
and access educational materials; it contains linked 
presentations, webinars and other educational material 
managed through the Umbraco content management 
system.  ere are three phases in its development, the 
ﬁ rst was launched in Paris in 2015. Preliminary work on 
content has concentrated on some of the topics high-
lighted as priority needs by National Societies. 
Two approaches are being used to acquire high 
quality material for the eAcademy. The first is using 
the present.me software, which enables powerpoint 
slides to be coupled with video and voiceover, to prepare 
short modules covering specific topics. The second is to 
identify interesting presentations at IFCC and National 
Society scientific meetings for recording and inclusion in 
the eAcademy. Appropriate presentations are identified 
from the published programmes for upcoming events. 
We need the support and help of National Societies 
to cooperate with us in arranging the recordings. It 
is through the generous financial support of Siemens 
that we are able to finance this approach.
A further part of the project is to identify high 
quality material published by other organisations and 
we are working with these materials, including EFLM 
and AACB, to allow link to distance learning modules 
on their websites. 
PL-1. Cooperation possibilities with IFCC. 
Update on the IFCC e-academy
Janet Smith1 
1 International Federation of Clinical Chemistry and Laboratory Medicine Milan, Italy
E-mail: janmsmith@Talk21.com
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PL-2. Proposal for the modification of 
the conventional model for establishing 
performance specifications
Wytze P. Oosterhuis1, Sverre Sandberg2
INTRODUCTION
A good quality of test results is fundamental to the 
work of the medical laboratory. How to define the level 
of quality needed is a question that has been subject to 
much debate, and more than one consensus agreement 
has been reached to define quality specifications [1–4]. 
Quality specifications have been defined on the basis of 
criteria derived from the clinical applicability, validity 
of reference limits and reference change values, state-
of-the-art performance, and other criteria, depending 
on the application and the characteristics of the test.
Quality specifications are often expressed as the 
total error allowable (TEA) – the total amount of error 
that is medically, administratively, or legally accept-
able. Following the TEA concept, bias and imprecision 
are combined into one number representing the 
“allowable” error in the result. Internal quality control 
( IQC) procedures, as well as external quality assess-
ment (EQA) can be shaped according to the TEA of 
the analyte [5]. The Six Sigma concept is also linked 
to TEA, as the sigma value is derived from this entity 
[5, 6]. “Sigma-metrics” are valuable to “normalize” 
quality to a common scale.
The commonly accepted method for calculation of 
the allowable error based on biological variation might, 
however, have room for improvement. The addition 
of the bias and imprecision terms according to this 
method has been shown to overestimate TEA [7]. In 
the present paper, we discuss the common theories on 
the determination of quality specifications. A modified 
model for the calculation of quality specifications is 
presented. The validity of reference limits and refer-
ence change values are central to this model that is 
a modification of existing models (further called the 
“modified model”) [8–10].
ANALY TICAL QUALIT Y SPECIFICATIONS
According to the new consensus [1], quality specifi-
cations for clinical applicability should preferably be 
based on clinical outcome, which for most situations 
is the same as specifications based on decision levels 
and evaluation of tolerable false-positive (and false-
negative) results. It was, however, acknowledged that, 
in many cases, this is difficult or even impossible to 
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achieve as for most analytes decision levels cannot be 
unambiguously defined. According to the consensus 
document, the preferred alternative approach for 
these measurands is to derive specifications from 
biological variation. It should be noted that there is 
a fundamental difference between these methods, as 
the specifications based on biological variation are 
not related to clinical needs but tries to minimize the 
“signal-to-noise” ratio between analytical variation and 
the (natural) biological variation.
Analytical performance specifications based on 
biological variation are now broadly used in clinical 
chemistry, whereas in clinical guidelines, performance 
based on clinical criteria is, in most cases, preferred 
[11, 12].
Cotlove et al. [13] proposed that the tolerable ana-
lytical variation (analytical standard deviation) should 
be less than half of the total biological variation:
CVA < 0.5CVB (CVB = coefficient of variation, 
total biological).
Harris [14] then proposed that quality specifica-
tions for individual monitoring should be calculated 
using the formula
CVA < 0.5CVI (CVI = coefficient of variation, 
within subject). 
For medical diagnosis, the total biological variation 
was used. In the case of monitoring to detect trends in 
the results from an individual over a period of time, the 
within-subject CVI is used instead of the total biological 
variation. This strategy was adopted by the College of 
American Pathologists at the 1976 Aspen Conference 
[3] and by the Subcommittee on Analytical Goals in 
Clinical Chemistry of the World Association of Socie-
ties of Pathology in London in 1978 [4, 8].
DEFINITION OF BIA S AND IMPRECISION
Mathematically, analytical bias is clearly different from 
imprecision. Bias or systematic measurement error is 
defined as an error that in replicate measurements 
remains constant or varies in a predictable manner 
[15]. However, it is also stated that, “Systematic 
measurement error, and its causes, can be known or 
unknown. A correction can be applied to compensate for 
a known systematic measurement error.” In practice, the 
distinction between bias and imprecision is, however, 
less clear. “Systematic” implies a certain time period. 
As Klee [16] pointed out, bias tends to be dependent 
on the time interval considered. In this paper, bias is 
used for the net shift in test values, relative to the set 
point of the assay when the reference data on patients 
were collected. Although bias should be removed when 
possible, in some circumstances, bias is inevitably 
encountered, such as systematic differences between 
analyzers measuring the same analyte.
TOTAL ERROR CONCEPT
The total error (TE) is an expression of the total devia-
tion of the test result from the true value. Westgard 
et al. [17] presented this TE concept using the argu-
ment that physicians think rather in terms of the 
total analytical error, which includes both random 
and systematic components.
The TE limits are defined by a maximum percentage 
of test results, generally taken as 5%, that exceeds this 
limit (one-sided). For example, assume the true value 
of a plasma glucose measurement is 9 mmol/L and 
assume the TE, calculated from actual bias and impre-
cision, is 10%. In that case, there is up to a 5% chance 
that this actual result will exceed the TE limit. This 
means that the probability that the true result will be 
< 8.1 mmol/L or will be > 9.9 mmol/L will each be 5%. 
Whether this result meets the quality criteria depends 
on the specification of the quality limits (see below).
The basic expression most generally used for calcu-
lation of the TE is [17]
TE = bias + Z × CVA.
The Z-value is generally taken as 1.65 (95% one-
sided) (Note 1).
TOTAL ERROR ALLOWABLE TE AAs shown above, TE can be calculated from actual bias 
and imprecision when these are known. However, when 
a limit for TE is predefined (the total error allowable, 
TEA), the maximum allowable bias and imprecision can 
be derived for the acceptable analytical performance. 
Medical decision levels should be specified, at which 
concentration the performance of a method is critical. 
Just as an example, one decision level for glucose could 
be at 2.8 mmol/L with a TEA of 20% (0.56 mmol/L). The 
maximum allowable bias and imprecision can then be 
calculated using
TEA = bias + Z × CVA.
Many combinations of bias and imprecision can 
meet the limit set by the value selected for TEA. In our 
example, the extreme values are bias = 20% (with CVA = 
0) and CVA = (20/1.65) = 12.1%. Bias and imprecision have 
a linear (inverse) relationship: a higher bias requires a 
low imprecision, a high imprecision a low bias. As will 
be shown below, this model is valid only when biological 
variation does not play a role.
QUALIT Y SPECIFICATIONS BA SED ON 
BIOLOGICAL VARIATION
Quality speciﬁ cations should preferably be based on 
clinical outcome.  e speciﬁ cation of TEA is not always as 
straightforward as mentioned before. An alternative is to 
derive these speciﬁ cations from biological variation [1].
How can this be achieved? Allowable imprecision 
and bias had been defined as follows:
(1)
(2)
(3)
(4)
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– Allowable imprecision CVA < 0.5CVI [14].
– Allowable bias < 0.25(CVI2 + CVG2)1/2 [8].
In the case of EQA, these specifications should be 
fulfilled separately and EQA schemes could be designed 
accordingly. Fraser and Hyltoft Petersen [18] proposed 
that in case only a single determination of each survey 
material is used or allowed, the 95% acceptance range 
for each laboratory from the target value was proposed 
to be the sum of both values:
95% acceptance range = 
target value ± [1.65(0.5CVI) + 0.25(CVI2 + CVG2)1/2].
In terms of the TEA:
TEA =1.65(0.5CVI) + 0.25(CVI2 + CVG2)1/2.
T WO FL AWS IN THE CONVENTIONAL MODEL
Although the purpose of expression (5) was the appli-
cation in EQA, it is commonly accepted and used for 
other purposes outside EQA, such as the identification 
of appropriate limits for IQC [5, 19].
As shown above, the quality specification for impreci-
sion is, in general, CVA < 0.5CVB. In the case of diagnosis, 
this can be written as CVA < 0.5(CVI2 + CVG2)1/2. In case 
of monitoring, only the within-subject variation is 
included: CVA < 0.5CVI.
The maximum allowable bias was derived as 0.25CVB 
or 0.25(CVI2 + CVG2)1/2 [8]. It should be noticed, however, 
that in the conventional model, this bias term is applied 
in the case of monitoring although this expression had 
been derived from a reference value model and only 
applies to diagnosis. For that reason, in the case of 
monitoring, we applied in the present study the refer-
ence change value model that is only based on CVI and 
not on CVG [9, 10, 20].
Secondly, it has been a pragmatic solution proposed 
for the use in EQA to add both maxima of allowable 
bias and imprecision to obtain TEA as in Eq. (5). The 
theoretical basis for this is, however, lacking, as two 
“maximum” errors are added, each allowing 5% of the 
test results exceeding the limit, and only valid under 
the mutual exclusive assumptions of zero bias and 
zero imprecision, respectively. The sum will allow an 
increase of the percentage of test results exceeding 
the predefined limits [7].
What could be a rational and correct alternative to 
combine the effects of bias and imprecision on patient 
test results?
THEORETICAL MODELS FOR QUALIT Y 
SPECIFICATIONS
Several models have been developed to derive maximal 
bias and imprecision based on reference values and the 
maximum number of false positives [8, 16]. The model 
presented here is the model according to Gowans et 
al. [8].
MODEL OF GOWANS APPENDIX 1
The model of Gowans et al. [8] (here referred to as 
the model of Gowans) is based on the influence of bias 
and imprecision on the proportion of results outside 
reference limits. Performance specif ications were 
derived from the maximum number of results outside 
the reference limits. In the model of Gowans, bias and 
imprecision are combined into one model. The inf lu-
ence on the false-positive rate is calculated based on 
a Gaussian distribution.
Owing to the effects of bias, imprecision, or a 
combination of both, more cases will be outside the 
reference limits. Instead of the usual 2.5% outside a 
reference limit at 1.96 SD, a maximum of 4.6% (based 
on the IFCC guideline on reference values [21]) outside 
the same limits was assumed to be acceptable. Thus, 
Gowans’ model allows a maximum increase of 84% 
(Note 2) in false-positive results.
Following Gowans’ model, a curve can be calcu-
lated that defines the maximum bias and imprecision 
with 4.6% of results outside the reference limit. The 
maximum bias and imprecision at the extreme ends 
of this curve are (see Appendix 1) discussed below.
The maximum allowable error was calculated as 
follows:
– Maximum bias (when imprecision = 0) = 0.275CVB.
– Maximum imprecision (when bias = 0) = 0.597CVB.
where CVB is the total biological variation (in this 
model, not further specified with respect to CVI and 
CVG).
Between these two extremes, a curve describes 
the combination of bias and imprecision such that the 
condition is fulfilled: 4.6% of the results outside the 
reference limits (one-sided) (Figure 1) (Note 3).
According to Gowans’ model, the maximum allow-
able bias (0.275CVB) only applies when CVA is minimal 
(the hypothetical situation with CVA = 0). On the other 
Figure 1: Model according to Gowans et al. [8].
Curved relation between bias and imprecision that describes 
the combinations of bias and imprecision with 4.6% of the 
results outside the upper reference limit.
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hand, when bias is minimal (bias = 0), the allowed 
CVA is at a maximum (CVA = 0.597CVB). This concept is 
clearly not in accordance with the model proposed by 
Fraser and Hyltoft Petersen, mentioned above, where 
maximum bias and maximum imprecision are summed 
in the expression of TEA.
It is important to note that TEA in Gowans’ model 
is not a constant but varies from 0.275CVB (at CVA = 0) 
to 1.65 (0.597CVB) (at bias = 0, with Z-factor = 1.65). See 
also Appendix 1: Gowans for calculation of maximum 
bias and imprecision of creatine kinase (CK) and 
sodium, and Table 1.
WHY WA S ANALY TICAL VARIATION 
NOT INCLUDED IN THE DEFINITION OF 
PERFORMANCE SPECIFICATIONS?
The starting point of the models of Gowans and others 
like the model of Klee [16] is the validity of reference 
l imits. The analytical performance specif ications 
of the tests are derived from this concept. Gowans’ 
model has the same assumption as the model of Klee: 
both define the reference limits without taking the 
analytical variation into account. This is clearly not 
the situation in common practice, as reference limits 
include analytical variation.
Why was this deﬁ nition of reference limits used 
without inclusion of the analytical variation?  e reason 
can be understood from the paper itself [8]: by including 
the analytical variation in the reference interval, the 
performance speciﬁ cation for analytical variation will, 
in part, be determined by the analytical variation itself.
DIFFERENT APPLICATIONS OF QUALIT Y 
STANDARDS
How to solve the problem of defining performance 
specifications without this circular argument involved 
in defining, applying, and controlling analytical quality?
Three different quality objectives should be sepa-
rated at this point. The first is the achievement of the 
minimum analytical performance needed for clinical 
use of a test – answering the question: is the quality of 
the assay acceptable for routine use? This is a concept of 
the clinical utility of a test. For this decision, different 
criteria can be applied here, as covered by consensus-
based quality specifications, e.g., CVA < 0.5CVI.
The second quality objective is the achievement 
of the minimum analytical performance to maintain 
the validity of the reference limits (or, in the case of 
monitoring, reference change values), corresponding 
to the situation at the time the test was taken into use.
Third is the inclusion of IQC into the concept. To 
maintain the minimum analytical performance, some 
extra quality margin is needed due to the limited 
sensitivity for bias and imprecision of IQC procedures 
(see below).
In the case of sodium, the analytical variation is 
generally higher than the biological variation.  e refer-
ence limits are, for the greater part, determined by the 
analytical variation, not by the biological variation. With 
quality criteria based on the presented models, the 
test would fail these quality requirements (in theory, 
this could be overcome by replicate measurements). 
 e quality could also be related to the state-of-the-art 
performance; however, this would mean that the required 
quality is not based anymore on any theoretical model, 
and the validity of reference intervals – according to 
the presented models – is not maintained.
We propose another approach, by which the quality 
specifications are based on the same principles but with 
an accurate calculation of reference limits or reference 
change values. For analytes with a high analytical vari-
ation relative to the biological variation, this would 
result in more realistic quality goals.
This approach is made independent of the criterion 
by which the test was approved for clinical use. In theory, 
even a low-quality test with a very high imprecision 
could be introduced as a routine test by a laboratory. 
This would result in reference limits and reference 
change values that are determined predominantly 
by the analytical variation. In that case, the modified 
model does still apply.
In the text below, quality specifications based on 
reference values are presented that apply in the case 
of diagnosis. It is acknowledged that most tests will be 
used for monitoring, and the model based on reference 
change values should be used. Mathematically, this 
model is very similar to the reference value model. For 
that reason and for reasons of readability, we refer to 
Appendix 3: performance specifications for the refer-
ence change model.
Table 1:  Quality specifications with maximum bias (at CVA = 0) and maximum imprecision (at bias = 0) based on different 
models for CK and Na.
Model
CK Na
Bias, % Imprecision, % Bias, % Imprecision, %
Conventional (monitoring) [22] 30.3 18.4 0.73 0.44
Gowans (diagnosis) 12.7 27.2 0.25 0.54
Modiﬁ ed (diagnosis) 12.7 27.1 0.39 1.34
Modiﬁ ed (monitoring) 9.0 13.7 0.28 1.30
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THE MODIFIED MODEL
This model is an adaptation of Gowans’ model (Appendix 
1), and the reference change values’ model [9, 10] 
(Appendix 3), based on the following principles:
1. The model describes the maximum bias and impre-
cision allowable that still maintains the validity of 
reference values (or reference change values in case 
of monitoring).
2. The reference limits are defined by both biological 
and analytical variation.
As in other models, a distinction is made between 
quality criteria for diagnosis and monitoring. For 
diagnosis, the CV of the reference value (CVref) is used 
as starting point:
CVref = (CVG2 + CVI2 + CVA02)1/2,
where CVA0 is the CV analy tical of the test at 
t = 0, when the reference limits were determined or 
confirmed.
CVG = CV(group) and CVI = CV (within person).
For monitoring, the reference change model is 
applied (see Appendix 3). This is an adaptation of the 
model as described before [9, 10]. In both cases, diag-
nosis and monitoring, the underlying mathematical 
principles are the same. The only difference is the 
description of the total variation.
The actual (total) variation of test results in a refer-
ence population is based on biological variation and 
CVA (CV actual analytical):
CVT(total) = (CVI2 + CVG2 + CVA2)1/2.
As in the model of Gowans, a maximum of 4.6% of 
the test results outside a reference limit is considered 
acceptable (any other percentage will not change the 
principle of the model).
The consequence of including CVA0 in the expression 
is that an increase in CVA with respect to CVA0 determines 
the quality, not the absolute value of CVA. In this model, 
CVA0 can be within the quality specification CVA < 0.5 
CVI but does not need to be, e.g., when the state of the 
art does not meet this specification. In the model of 
Gowans, a Gaussian distribution is assumed with CV = 
CVB with reference limits at the point where 2.5% of the 
results are outside the limits. Analytical variation (or 
analytical variation in combination with bias) is then 
added to the model with a limit of 4.6% test results 
outside the reference limits (in other words, 4.6% 
misclassification instead of 2.5%). In contrast to this, 
the modified model starts with a Gaussian distribution 
with CV = (CVB2 + CVA02)1/2 to which additional analytical 
variation (or analytical variation in combination with 
bias) is then added.
With CVA = 0, the maximum bias is
Biasmax = 0.275(CVB2 + CVA02)1/2.
With bias = 0, the maximum imprecision is
CVA,max = ((1.96/1.68)2 × (CVB2 + CVA02) − CVB2)1/2.
The model can be illustrated by the examples in 
Figures 2 and 3 for CK and sodium.
Figure 2: Curves describing the combinations of bias and 
imprecision for CK according to Gowans’ and the modified 
models.
The arrow indicates the position of CVA0 (see Appendix 2). 
Owing to the low value of the analytical compared to the 
biological variation, both models are almost identical.
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Figure 3: Curves describing the combinations of bias and 
imprecision for sodium according to Gowans’ and the modified 
models.
Owing to the high value of the analytical compared to the 
biological variation, both models differ considerably. The 
arrow indicates the position of CVA0 (see Appendix 2). The 
analytical variation is clearly outside the specifications of 
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QUALIT Y CONTROL, TE A, AND THE SIGMA 
CONCEPT
One of the most important uses of quality specifications, 
in terms of maximum allowable bias and imprecision, 
is the development of an IQC program. An important 
concept here is the TEA. TEA combines bias and impre-
cision to one fixed number. This concept is only valid 
when bias and imprecision show a linear relation (see 
Appendix 4: linear). The fixed number for TEA also means 
Eesti Arst 2016;95(Supplement 1):1–72 17
PLENARY LECTURES
that one does not need to know whether the deviation 
of a control sample result should be attributed to an 
increase of bias or imprecision. Only one limit TEA for 
the combination of bias and imprecision suffices.
The TEA concept is valid when IQC results are 
considered. The distribution of quality control results is 
described by the analytical variation only, as biological 
variation plays no role here. For these results, a TEA 
limit can be defined for the combination of bias and 
imprecision; bias and imprecision will show a linear 
relation as described in Appendix 4.
A problem arises, however, when this concept is 
translated to patient data. As we have shown, both in 
the concept of reference values and of reference change 
values, there is no linear relation between bias and 
imprecision. When biological variation is taken into 
account, the linearity changes to a curved relation. This 
curved relation implies that the tolerance for additional 
imprecision will increase compared to the tolerance for 
additional bias, which will remain unchanged. (What 
might also be taken into consideration is the fact that 
the sensitivity of multirules [17] are not the same for 
bias and imprecision.)
Now the problem can be described more precisely: 
when we have an ICQ result with a certain deviation 
from the target value, we cannot ascribe this to an 
effect of bias or imprecision. In a linear model, we have 
shown that this is not of importance, as long as the 
deviation is within the TEA limits. As the TEA concept 
fails with patient results, with no linear relation between 
bias and imprecision, how can we decide whether this 
deviation is acceptable or not?
There is no accepted solution for this problem. We 
could, however, assume that the imprecision of the test 
system will remain constant. With that assumption, 
deviations of IQC results will be ascribed solely to the 
effect of bias. This pragmatic solution would result in 
a definition of TEA for quality control results as
TEA = bias + Z × CVA.
With (for diagnosis):
Z = 1.65.
with CVA = CVAO (see Appendix 2).
CVTO = (CVI2 + CVG2 +CVAO2)1/2.
Biasmax = − 1.68CVTO + 1.96CVTO = 0.275CVTO.
TEA = 0.275CVTO + 1.65CVAO.
For monitoring, see Appendix 3: modified RCV.
A test can have a certain analytical quality that is 
close to the limit of the quality specifications. In that 
case, there will be a problem with the maintenance of 
this level of quality. For instance, when CVA = 0.5CVB 
(see Figure 1), the analytical variation is almost equal to 
the limit of the desired quality specification according 
to the criteria based on biological variation [23]. In 
Gowans’ model, no additional bias or imprecision is 
allowed. This makes it almost impossible to apply 
quality control specifications to the test, even with 
the quality specification fulfilled. The modified model, 
however, has a considerable margin for additional bias 
and imprecision in the case of CK (Figure 2, vertical 
line), and some margin for sodium (Figure 3). 
In conclusion, some extra margin of quality is needed 
because of the limited sensitivity of ICQ procedures. 
Note that within the Six Sigma theory, a margin of 1.5 
SD is assumed necessary to maintain the results within 
the performance specifications.
DISCUSSION
In this study, we compared several models for analytical 
quality specifications, including a modified model 
based on the calculation of reference values and refer-
ence change values, taking the analytical variation 
into account. Central to this model is the assumption 
that the validity of reference limits (for diagnosis) or 
reference change values (for monitoring) determines 
the minimum analytical quality. This concept can, of 
course, in itself be discussed.
A distinction is made with, on the one hand, the 
analytical performance needed for routine clinical use of 
a test, answering the question of whether a test should 
be taken into routine use by the laboratory. On the 
other hand is the analytical performance required to 
maintain the validity of the reference limits and refer-
ence change values, once the choice has been made to 
take a test into use. The second follows the first: when 
a test is accepted for routine use based on clinical or 
other criteria, reference limits are subsequently deter-
mined (or existing reference limits validated). Quality 
criteria can subsequently be derived from the model 
that maintains the validity of the reference limits or 
reference change values.
Both models of Klee and Gowans [8, 16] are based 
on the reference value concept and do include the 
biological variation, but do not include analytical varia-
tion in their definition of reference limits. This can lead 
to unrealistic values and quality criteria for tests like 
sodium, where the analytical variation is the dominant 
component of the reference interval.
 e calculation of TEA is often based on biological 
variation. It has been shown that in the calculation of 
TEA, the summation of both maximum allowable bias and 
imprecision term [expression (2)] does lack a theoretical 
basis [7]. In the conventional model, the total allowable 
error is assumed to be a constant, with an inherent linear 
relation between bias and imprecision.  e biological vari-
ation is, however, not correctly included in this model. 
In the presented model, TEA – with analytical variation 
included – is not anymore a constant but depends on the 
ratio of bias and analytical variation.
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The proposed modified model can be seen as an 
adaptation of existing models based on reference values 
[8] and reference change values [9, 10]. In these models, 
reference limits were calculated based on biological 
variation alone. In the present model, reference limits 
are based on both biological and analytical variation. 
In tests with CVB considerably larger than CVA, CVA 
can, however, be neglected in the calculation, and 
the model equals to the existing models. When this 
condition is not fulfilled, the quality goals according 
to the existing models will tend to be too strict. For 
example, for sodium, it would be almost impossible to 
meet the quality specifications (Figure 2). In contrast, 
in the modified model, both bias and imprecision do 
meet the quality specifications and have still some 
margin for increase. In the case of a less-than-perfect 
test, application of the modified model will lead to 
more realistic quality goals.
In the model of Gowans, the quality specification 
for misclassification was 4.6%. In the presented model, 
we applied this specification of 4.6% both for the case 
of diagnosis and for monitoring, although in the model 
of Gowans this specification has been derived for the 
validity of reference values (and thus for diagnosis) 
only. Another specification could, however, be applied, 
without changing the principles of the presented model.
On the one hand, we have quality specifications 
based on the validity of reference values and reference 
change values. On the other hand, we have the problem 
of maintaining this quality with quality control proce-
dures. These procedures have a limited sensitivity for 
errors, and an extra quality margin is needed to be able 
to guarantee that results are within quality limits. This 
margin will depend on the quality control procedures 
applied, and is not part of the models presented here.
CONCLUSIONS
We propose a modified model that offers an alternative 
method for the calculation of performance specifica-
tions. It is based on maintaining the validity of refer-
ence limits and reference change values. The model 
applies to almost any test if biological variation can 
be estimated. A pragmatic method for the design of 
IQC is presented.
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NOTES
Note 1
Z-value 1.65 vs. 1.96.
When the bias is equal or larger than the analytical 
imprecision, the Z-value of 1.65 applies, and 95% of the 
test results will fall within the limits defined by the 
TEA. The test result can be reported with 95% certainty 
to be within the limit defined by this TEA.
The Z-factor has been shown to be dependent on the 
ratio of bias and imprecision and could be 1.96 (twosided 
0.95 or 95% confidence limit) when bias can be neglected 
compared to the imprecision. For ratios of bias and 
imprecision, the Z-value was calculated as 1.96 (bias/
imprecision = 0), 1.77 (ratio = 0.25), 1.68 (ratio = 0.5), 
1.65 (ratio = 0.75), and 1.645 (ratio ≥ 1) [24].
For example, when the true value of glucose is 9 mmol/L 
with a bias of 6% and an imprecision of 2% (ratio > 1), 
then the bias is 9 mmol/L × 6/100 or 0.54 mmol/L and 
the imprecision 9 mmol/L × 2/100 or 0.18 mmol/L. This 
makes TE 0.54 + 1.645 × 0.18 or 0.84 mmol/L greater 
than the actual concentration of 9.0 mmol/L, so that 
the TE limit is 9.84 mmol/L.
In this case, the bias is positive and substantially 
greater than the imprecision. The Z-value is 1.645 in 
this case, as only the upper limit is relevant: knowing 
with 95% certainty that the true glucose concentra-
tion will not exceed the 9.84 mmol/L limit. With this 
bias, the measured value will never be lower than the 
true value.
If, on the other hand, the bias is low, the Z-value 
of 1.96 should be applied. For example, when the true 
value of glucose is 9 mmol/L with a bias of 0% and 
an imprecision of 2%, then Z is 1.96. The imprecision 
component is 9 mmol/L × 1.96 × 2/100 or 0.35 mmol/L. 
This makes the TE 0.0 + 0.35 or 0.35 mmol/L higher or 
lower than the actual concentration of 9.0 mmol/L so 
that the TE limits are 8.65 and 9.35 mmol/L.
As a known bias can be corrected, the presence of 
a bias that is equal or larger than the imprecision of a 
test should, in many cases, be corrected. As a result, use 
of the Z-value of 1.65 in all cases could be questioned.
Note 2
Gowans’ model allows a maximum increase of 84%: 
(4.6–2.5)/2.5 × 100% = 84%.
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Note 3
Note that these results are in close agreement with the 
accepted performance criteria [25]: for bias, compare 
0.275CVB (CV biological) with the maximum (desirable) 
bias of 0.25CVB.
For imprecision, compare 0.597CVB with 0.5CVI. 
Note that Gowans’ model only mentioned biological 
variation and did not take into account the differ-
ence between diagnosis (based on within group and 
within person variation) and monitoring (based only 
on within-person variation).
APPENDIX
Appendix 1. Model of Gowans et al. (Gowans)
When the recommendations of the IFCC are applied, 
reference values will be calculated on the basis of test 
results in a group of at least 120 persons [21].  ere is 
always an inherent uncertainty in the determination of 
the reference limits for every analyte.  is uncertainty is 
such that with n = 120, a maximum of 4.6% (one-sided) 
of the results could be outside the “inner” conﬁ dence 
limit of the reference limits when using 1.96 SD.
Following this model, a curve can be calculated that 
defines the maximum bias and imprecision with 4.6% 
of results outside the reference limit. Maximum bias 
and imprecision are at the extreme ends of this curve 
are (see Figure 1).
In general, the relation between bias and impreci-
sion can, in this case, be described as (see Appendix 4)
Bias = −1.68CVT + 1.96CVB,
with CVT = total variation = (CVB2 + CVA2)1/2; CVB = 
total biological variation; CVA = analytical variation; 1.96 
represents the Z-value with 2.5% and 1.68 the Z-value 
with 4.6% outside the limit.
In this expression, bias and imprecision (analytical 
variation) have a linear relationship with a slope of 
–1.68 (see Appendix 4). The intersection with the y-axis 
represents the bias at CVA = 0:
Bias(CVA = 0) = –1.68(CVB2 + CVA2)1/2 + 1.96CVB
= –1.68(CVB2)1/2 + 1.96CVB
= (1.96 – 1.68)CVB.
Maximum bias (when imprecision = 0) = 0.275CVB.
Note that this number differs from 0.25 in the study 
of Gowans et al. [8].
The intersection with the x-axis represents CVA at 
bias = 0
CVA(bias = 0) : 0 = –1.68(CVB2 + CVA2)1/2 + 1.96CVB.
1.96CVB = 1.68(CVB2 + CVA2)1/2.
Maximum imprecision (when bias = 0) = 0.597CVB.
Between these two extremes, a curve describes 
the combination of bias and imprecision such that the 
condition is fulfilled: 4.6% of the results outside the 
reference limits (one-sided) (Figure 1) (Note 3).
Calculation of maximum bias and imprecision of 
CK and sodium:
Example 1: CK
Gowans’ model, with maximum imprecision and bias, 
respectively:
CVA,max = 0.597CVB.
Biasmax = 0.275CVB.
CVI = 22.8%; CVG = 40.0% [22].
CVB = (CVI2 + CVG2)1/2 = 46.0%.
CVA,max = 0.597CVB = 27.2%.
Biasmax = 0.275CVB = 12.65%.
Example 2: sodium
CVI = 0.6%; CVG = 0.7% [22].
CVB = (CVI2 + CVG2)1/2 = 0.92%.
CVA,max = 0.597CVB = 0.54%.
Biasmax : 0.275CVB = 0.25%.
Note that these quality limits apply for diagnosis, 
not for monitoring situations.
Appendix 2. Modified model, adapted Gowans’ 
model
Below is the modification of Gowans’ model, based on 
the following principles:
1.  The model describes the maximum bias and impre-
cision allowable to maintain the validity of refer-
ence values (or reference change values in case of 
monitoring).
2.  The reference limits are defined by both biological 
and analytical variation.
As in other models, a distinction is made between 
quality criteria for diagnosis and monitoring. For 
diagnosis, the CV of the reference value (CVref) is used 
as starting point:
CVref = (CVG2 + CVI2 +CVAO2)1/2,
with CVA0 = CV analytical of the test at t = 0, when 
the reference limits were determined or confirmed; 
CVA = CV actual analytical.
For monitoring, the reference change model is 
applied (see Appendix 3). This is an adaptation of the 
model as described before [9, 10]. In both cases, diag-
nosis and monitoring, the general principles presented 
here are the same.
The actual (total) variation CVT of test results in a 
reference population is based on biological variation 
and actual analytical variation CVA:
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CVT = (CVI2 + CVG2 +CVA2)1/2.
As in the model of Gowans, a maximum of 4.6% of the
test results outside a reference limit is considered 
acceptable (any other percentage is, however, possible 
and will not change the principle of the model). The 
curve in this modified model is identical to the curve 
according to Gowans, with the following substitutions.
The relation between bias and imprecision can, in 
this case, be described as (see Appendix 4)
Bias = –1.68(CVB2 + CVA2)1/2 + 1.96(CVB2 + CVAO2)1/2
= –1.68(CVI2 + CVG2 + CVA2)1/2 + 1.96(CVG2 + 
CVI2 + CVAO2)1/2.
CVB = (CVI2 + CVG2)1/2,
where 1.96 represents the Z-value with 2.5% and 1.68 
the Z-value with 4.6% outside the limit, respectively.
The consequence of including CVA0 in the expres-
sion is that an increase in CVA with respect to CVA0 
determines the quality, not the absolute value of CVA.
In the model of Gowans, a Gaussian distribution is 
assumed with CV = CVB with reference limits at the 
point where 2.5% of the results are outside the limits. 
Analytical variation (or analytical variation in combi-
nation with bias) is then added to the model with a 
maximum of 4.6% test results outside the reference 
limits. In contrast to this, the modified model starts 
with a Gaussian distribution with CV = (CVB2 + CVA02)1/2 
to which analytical variation (or analytical variation 
in combination with bias) is then added.
With bias = 0, the maximum allowable imprecision 
should fulfill the condition
Bias = 0 = –1.68(CVB2 + CVA,max2)1/2 + 
1.96(CVB2 + CVAO2)1/2.
The maximum CVA can be calculated from this 
expression to be
CVA,max = ((1.96 / 1.68)2 × (CVB2 +CVAO2) − CVB2)1/2.
With CVA = 0, the maximum bias is
Biasmax = 0.275(CVB2 +CVAO2)1/2.
The model can be illustrated by the examples in 
Figures 1 and 2.
Example 1: CK
In the case that CVA0 < < CVB, the term CVA0 vanishes 
from the expression and the modified model equals 
Gowans’ model (Figure 1), with maximum imprecision 
and bias, respectively
CVA,max = 0.597CVB.
Bias max = 0.275CVB.
Note that, in this case, the modified model will 
become equal to Gowans’ model.
CK approximates this condition with CVA0 << CVB. 
Numbers from the authors’ laboratory:
CVA0 = 1.17%.
CVI = 22.8%; CVG = 40.0% [22].
The contribution to the reference interval by the 
analytical variation is only 0.03%.
Note:
CVI = 22.8%; CVG = 40.0%.
(CVI2 + CVG2 +CVAO2)1/2 = (22.82 + 40.02 + 1.172) 1/2 = 46.01%.
(46.01 − 46.0) / 46 × 100% = 0.03%.
CVA,max according to the modified model:
(CVbiol2 + CVA,max2)1/2 = 1.16(CVbiol2 + CVAO2)1/2 −> 
CVA,max = 27.1%.
Biasmax = 0.275(CVbiol2 + CVAO2)1/2 = 12.65%.
This illustrates that for CVA0 << CVB, both models 
become equal.
Example 2
On the other end of the spectrum, we have CVA0 >> 
CVB, and now the term CVB vanishes from the expres-
sion. Gowans’ model does not apply to this situation, 
as CVA0 lies outside the area of the curve (outside the 
minimum quality limit).
Sodium approximates this condition with CVA0 > CVB. 
Numbers from the authors’ laboratory (see Figure 2):
CVA0 = 1.06%.
CVI = 0.6%; CVG = 0.7% [22]; CVB = 0.92%.
The contribution to the reference interval by the 
biological variation is 17%.
CVA,max, modified model:
(CVB2 + CVA,max2)1/2 = 1.16(CVB2 + CVAO2)1/2 −> 
CVA,max = 1.34%.
Biasmax = 0.275(CVB2 + CVAO2)1/2 = 0.39%.
Appendix 3. Performance specification based 
on reference change values
Modified model
Below is the adaptation of the model based on refer-
ence change value [9, 10], according to the following 
principles:
1.  The model describes the maximum bias and impreci-
sion necessary to maintain the validity of reference 
change values.
2.  The reference change values are defined by both 
biological and analytical variation.
3.  By definition, reference change values only apply 
for monitoring, not for diagnosis.
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The reference change value (RCV) is defined as
RCV = 2 × Z × (CVI2 + CVA2)1/2,
CVA = CV analytical,
CVI = CV within person,
where Z is the number of standard deviations 
appropriate to the desired probability.
The differences between two consecutive values 
within one patient are described by a Gaussian curve 
with CV:
CVRCV = 2(CVI2 + CVA2)1/2.
With a Z-value of 1.96, 2.5% of the test results will 
respectively be outside the upper and lower limits. In 
analogy with the quality limits described before, we 
chose to set the quality standard at a maximum of 
4.6% outside upper and lower limits, instead of 2.5%. 
In other words, bias and imprecision – or the combi-
nation of these – are allowed to increase until 4.6% of 
the differences (change values) of a reference popula-
tion are outside a reference limit, resulting in a 4.6% 
misclassification instead of 2.5%.
Again, we substitute CVA0 (CVA at the time the test 
was introduced or validated) for CVA. The consequence 
of this is that it is the increase in CVA with respect 
to CVA0 that determines the quality, not the absolute 
value of CVA.
RCV = 2 × Z × (CVI2 + CVAO2)1/2.
The combinations of maximum bias and imprecision 
are again described with a curve.
With imprecision = CVA0, there is no additional 
imprecision compared to CVT0, and the maximum bias 
can be calculated (a decrease of imprecision relative to 
CVT0 is possible but not considered here):
Bias = 1.96 × 2CVTO – 1.68 × 2CVT.
Note: 1.96 is Z-value corresponding with 2.5%; 1.68, 
with 4.6% outside the quality limit.
With CVTO = (CVI2 + CVAO2)1/2,
CVT = (CVI2 + CVA2)1/2.
Maximum bias is allowed when CVA = CVA0, and 
CVT = CVT0
Biasmax = (1.96 − 1.68) × 2CVTO,
or
Biasmax = 0.275 × 2(CVI2 + CVAO2)1/2.
With bias = 0, the maximum allowable imprecision 
should fulfill the condition:
Bias = 0 = 1.96 × 2CVTO – 1.68 × 2CVT,
With CVT0 = (CVI2 + CVAO2)1/2,
And CVT = 2(CVI2 + CVA2)1/2,
Bias = 0 = 1.96 × 2(CVI2 + CVAO2)1/2 − 
1.68 × 2(CVI2 + CVA2)1/2.
The maximum CVA can be calculated from this 
expression to be
CVA,max = ((1.96 / 1.68)2 × (CVI2 + CVAO2) − CVI2)1/2.
Example 1
CK approximates this condition with CVA0 < < CVB. 
Numbers from the authors’ laboratory:
CVA0 = 1.17%.
CVI = 22.8% [22].
CVA,max according to the reference change model:
CVA,max = ((1.96 / 1.68)2 × (CVI2 + CVAO2) − CVI2)1/2 = 13.7%.
Maximum bias:
Biasmax = 0.275 × 2(CVI2 + CVAO2)1/2 = 8.97%.
Example 2
Sodium approximates the condition with CVA0 > CVB. 
Numbers from the authors’ laboratory (see Figure 2):
CVA0 = 1.06%.
CVI = 0.7% [22].
CVA,max according to the reference change model:
CVA,max = ((1.96 / 1.68)2 × (CVI2 + CVAO2) − CVI2)1/2 = 1.3%.
Maximum bias:
Biasmax = 0.275 × 2(CVI2 + CVAO2)1/2 = 0.28%.
Estimated TEA for monitoring
TEA = bias + Z × CVA,
with (for monitoring)
Z = 1.65.
CVA = CVA0.
CVTO = (CVI2 + CVG2 + CVAO2)1/2.
Bias = −1.68 × 2CVTO + 1.96 × 2CVTO = 0.275 × 2CVTO 
= 0.39CVTO.
TEA = 0.39CVTO + 1.65CVAO.
Appendix 4. Linear relation between bias and 
imprecision
Assume that test results show a normal (Gaussian) 
distribution with coefficient of variation CVT0 (total 
coefficient of variation at t = 0, biological and analyt-
ical combined). We can define a limit (e.g., a quality 
limit) with a fixed number (percentage) of test results 
outside this predefined limit. The position of this 
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We assume that the actual CVA is equal to the CVA 
at time = 0 (stable CVA):
CVA = CVA0.
For diagnosis, the total variation at t = 0:
CVTO = (CVI2 + CVG2 + CVAO2)1/2.
For bias (see Appendix 4: linear):
Bias = –1.68(CVI2 + CVG2 + CVA2)1/2 + 
1.96(CVG2 + CVI2 + CVAO2)1/2.
With CVA = CVA0 [5], this becomes
Bias = −1.68CVTO + 1.96CVTO = 0.275CVTO.
Expression (1) combined with (2), (3), and (6) 
becomes
TEA = 0.275 × CVTO + 1.65CVTO.
Compare this with the expression for monitoring 
(Appendix 3: RCV):
Bias = 1.96 × 2(CVI2 +CVAO2)1/2 − 
1.68 × 2(CVI2 +CVA2)1/2.
With CVA = CVA0 [5], this becomes
Bias = 0.275 × 2(CVI2 +CVAO2)1/2.
Expression (1) combined with (2), (3), and (6) 
becomes
TEA = 0.275 × 2(CVI2 +CVAO2)1/2 + 1.65CVAO.
TEA = 0.39(CVI2 +CVAO2)1/2 + 1.65CVAO.
For CK, this will give a sigma score (numbers as 
used before):
With CVA0 = 1.17%; CVI = 22.8%.
TEA = 10.8%.
Sigma score (with CVA = CVA0) : TEA/CVA0 = 9.3.
For sodium:
With CVA0 = 1.06%; CVI = 0.6%.
TEA = 2.2%.
Sigma score (with CVA = CVA0) : TEA/CVA0 = 2.1.
It can be calculated that for a sigma score of 3.0, 
CVA (with CVA = CVA0) should be 0.18%.
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analytical variation can be neglected. For diagnosis:
TEA = bias + Z × CVA,
with
Z = 1.65.
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The profession of Laboratory Medicine differs between 
countries within the European Union (EU) in many 
respects. The objective of professional organizations for 
promotion of mutual recognition of specialists within 
the EU is closely related to the free movement of people. 
This policy translates to equivalence of standards and 
harmonization of the training curriculum. In a study 
that was supported by both the Union Européenne de 
Médecins Spécialistes (UEMS) and European Federation 
of Clinical Chemistry and Laboratory Medicine (EFLM), 
the organization and practice of Laboratory Medicine 
was evaluated within the countries that constitute 
the EU. A questionnaire covering many aspects of 
the profession was sent to delegates of the EFLM and 
UEMS of the 28 EU countries. The results were sent 
to the delegates for confirmation. Many differences 
between the countries were identified: predominantly 
medical or scientific professionals; broad or limited 
professional f ield of interest; inclusion of patient 
treatment; formal or absent recognition; regulated or 
absent formal training programme; general or minor 
application of a quality system based on ISO Norms. 
Harmonization of the postgraduate training of both 
clinical chemists and laboratory physicians has been a 
goal for many years. Differences in the organization of 
the laboratory professions still exist in the respective 
countries which all have a long historical development 
with their own rationality. It is an important challenge 
to harmonize our profession, while difficult choices 
should be made. Recent developments with respect to 
the directive on Recognition of Professional Qualifica-
tions call for new initiatives to harmonize Laboratory 
Medicine both across national borders, and across the 
borders of scientific and medical professions.
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ORAL PRESENTATIONS
OP-1. Improving the efficiency of clinical 
laboratory services
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Automation of laboratory analyses over the past 50 
years has greatly increased efficiency in terms of the 
speed with which analytical results become available but 
speed is not the only factor contributing to efficiency. 
It is also important to maintain quality. More recently, 
the extension of automation to both the pre- and post-
analytical phases has not only improved turnaround time 
but reduced opportunities for human error.
However, analysis is not the only process to be consid-
ered. By examining overall workflow, using management 
techniques such as LEAN principles, wasteful steps can 
be eliminated and processes streamlined. Efficiency is 
improved by standardised practice, has developed to 
ensure quality and hence reduce errors. Use of such 
management techniques is dependent on teamwork and 
a committed, highly trained workforce.
Improvement of efficiency should not be considered 
in isolation. It is essential that service users are involved 
in defining the level of service expected as well as in 
defining what is required for appropriate patient care. 
Also, collaboration with other laboratories, for example 
in terms of sharing instrumentation or in decisions on 
which tests to offer on site, may provide further opportu-
nities for more effective and efficient provision of service.
OP-2. Laboratory management through 
consolidation / automation
Herbert Stekel – Institut für medizinische und 
chemische Labordiagnostic, Kepler Universitätsklinikum 
GmbH, Linz, Austria
Consolidation and automation are a central issue in 
simplifying the laboratory process. We will show, using 
some examples, how automation has developed step by 
step. The next breakthrough is consolidation. It leads 
to complex work areas, speeds up the workf low and 
changes the job content of all professional categories in 
the laboratory. High throughput, support by information 
systems and consolidated work areas are characteristic 
of an up-to-date laboratory. We will also present some 
facts and calculations showing how parameters like 
turn-around-time are affected by these changes.
LIS: the basics
Following our understanding of the laboratory process, 
we will show how single steps in this process can be 
supported by a LIS. We start with the request and the 
different ways to communicate between requester and 
laboratory. Next we will present some examples of how 
the steps of the process within the laboratory can be 
supported. At last we will demonstrate different ways how 
to bring the results from the laboratory to the clinician. 
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OP-3. Laboratory consolidation: a Finnish 
example of networking
Ari Miettinen – Fimlab Laboratories, Tampere, Finland
Over the last two decades technological innovations 
have created the potential for substantially improving 
the productivity of clinical laboratories. In many coun-
tries, however, the organization and business model of 
laboratories suffer for fragmentation, redundancy, and 
low capacity utilization. The monopoly position of many 
hospital laboratories as well as generous reimbursement 
policies may have allowed laboratories to become stuck 
with traditional specialty-defined models of organiza-
tion and production. Hence, technological advancements 
have not brought about cost savings to the degree that 
might have been anticipated.  
In the early 2000s the pressure to reduce healthcare 
costs focused the attention of the Finnish government 
on the way the country’s diagnostic services were organ-
ized. A government initiative was proposed to the public 
healthcare authorities with a view to reorganizing diag-
nostic services throughout the country in accordance 
with the consolidation and networking process of Fimlab 
Laboratories in its area. Moreover, a cut was made in 
reimbursements in order to boost a similar development 
in the private sector.
Within 15 years the number of laboratories within 
the public sector has decreased from more than 400 
independent laboratory units to 11 regional network 
organizations. The five largest of these cover about 4.5 
million (85%) of Finland’s total population of 5.3 million 
people. A similar consolidation process through acquisi-
tions and networking has taken place among the private 
clinics and their laboratories. 
As a consequence of consolidation and networking, 
the productivity of the laboratory branch has increased 
dramatically compared to that of the Finnish healthcare 
sector in general. Additional value has been created 
through harmonization and the availability of test results 
within the networks. An endpoint to the consolidation 
process is not yet in sight.
OP-4. Quality indicators in laboratory 
medicine: from theory to practice
Agnes Ivanov – Tartu University Hospital, Tartu, Estonia
E-mail: agnes.ivanov@kliinikum.ee
Identification and measurement of quality indicators 
(QIs) in the whole testing process (TTP) are obligatory 
requirements for accreditation of laboratories. A model 
of quality indicators (MQI) has been consensually devel-
oped by a group of clinical laboratories on the basis of a 
project launched by the Working Group of the Interna-
tional Federation of Clinical Chemistry and Laboratory 
Medicine (IFCC). The model includes 27 QI related to key 
processes (12 pre-, 5 intra- and 5 post-analytical phases) 
and 5 to support and outcome processes. The QI are 
divided, according to priority, into 4 classes: mandatory, 
important, suggested and valued. It is expected that this 
approach will be used in all kind of medical laboratories 
thus focusing on patient safety. 
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OP-5. Monitoring new oral anticoagulants
Lotta Joutsi-Korhonen – Coagulation disorders, HUSLAB 
Laboratory Services, Helsinki University Hospital, 
Helsinki, Finland
E-mail: Lotta.joutsi-korhonen@hus.fi
Direct oral anticoagulants (DOACs), the thrombin 
inhibitor dabigatran and the factor Xa (FXa) inhibitors 
rivaroxaban, apixaban and edoxaban are in clinical use in 
many countries. Clinical trials confirm that DOACs may 
be used for prevention of stroke in atrial fibrillation and 
for prevention and treatment of venous thromboembolism 
effectively and safely, without dose adjustment based on 
laboratory testing. The predictable pharmacodynamics 
and kinetics of DOACs make routine coagulation testing 
unnecessary. However, there are circumstances in which 
laboratory measurements are indicated and even vital. 
In case of acute hemorrhage or thrombosis, emergency 
surgery, reversal of anticoagulation, or renal dysfunc-
tion, clinicians may desire to determine the presence 
or concentration of a drug. 
Numerous laboratory assays may reveal the effects of 
DOACs. The widely available routine coagulation assays 
INR, PT and APTT, lack sensitivity and are inadequate for 
drug monitoring. A normal APTT most likely excludes 
excess dabigatran levels, and normal thrombin time 
(TT) excludes clinically relevant levels. Dilute-TT and 
ecarin-based assays can quantify dabigatran. The FXa 
inhibitors may be quantified with an anti-FXa assay 
calibrated with drug-specific standards. Among others, 
Russel’s Viper Venom Time and thrombin generation 
assays yield interesting findings for research. On the 
contrary, DOACs impact specialty coagulation assays 
potentially causing in vitro false results.
Limitations of coagulation testing should be noted. 
Initially, most data are based on drug-spiked plasma 
studies rather than on samples from real-life patients 
receiving DOAC therapy in clinical settings. Inter-indi-
vidual variation is obvious, and coagulation methods 
are reagent- and laboratory-dependent. Thus, available 
data must be interpreted with caution and more data is 
needed in order to establish alert values for clinicians. 
Laboratory could also guide the economical use of new 
reversal agents. These new settings of anticoagulation 
treatment represent a challenge for clinical laboratories. 
OP-6. Permanent fight between Owren and 
Quick
Valdas Banys – Department of Physiology, Biochemistry, 
Microbiology and Laboratory Medicine, Vilnius 
University, Vilnius, Lithuania; Vilnius University Hospital 
Santariskiu Klinikos, Center of Laboratory Medicine; 
Lithuanian Society of Laboratory Medicine, Vilnius, 
Lithuania
E-mail: valdas.banys@santa.lt 
The story of Owren and Quick began early in the last 
century. Back in 1935 Armand James Quick (1894–1978) 
developed a prothrombin time (PT) assay, where excess 
of thromboplastin and calcium is added to anticoagulated 
plasma. Later, in 1959 Paul Arnor Owren (1905–1990) 
created a modified PT version. His main objective was 
to overcome the drawbacks of the Quick method. Since 
then the two PT methods has been competing. Each has 
its own supporters, Quick having almost 90 percent of 
the total. Nevertheless, minor popularity of Owren does 
not mean that it is worse. Thus the aim of the speech is 
to provide the cons and pros of both methods. 
There are three basic technical differences between 
Owren and Quick PTs. First, Quick PT measures coagu-
lation factors FI, FII, FV, FVII and FX, and Owren PT 
measures only FII, FVII and FX. Consequently, Quick 
has an advantage in the diagnosis of coagulation factor 
deficiencies, since it measures the coagulation factor FV. 
However, it is a drawback in oral anticoagulation treat-
ment (OAT) follow-up, since OAT medication does not 
affect FV synthesis. Second, test mixtures differ in the 
amount of constituents (Quick: sample 50 μl + reagent 
100 μl; Owren: sample 10 μl + diluent 50 μl + reagent 
140 μl). Quick reagent`s volume is 40% smaller which 
means lower expenses per test. Third, sample volumes in 
a reaction mixture are different (Quick’s – 33%; Owren’s 
– 5%). This means that the Quick method is more sensi-
tive to pre-analytical variables such as heparin, citrate 
concentration and some other drugs.
Literature provides data that agreement between 
Owren and Quick PT’s is poor. This might compromise 
not only monitoring of individual patients, but also 
application of oral anticoagulation guidelines and trial 
results in clinical practice. Some authors have shown that 
Owren PT is much more consistent in a OAT setting, and 
have hence postulated a quite challenging question: “Has 
time arrived to replace the Quick PT test for monitoring 
OAT?” The answer cannot be straightforward. 
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OP-7. Screening for hemoglobinopathies
Marika Pikta – North Estonia Medical Centre, Tallinn, 
Estonia
E–mail: marika.pikta@regionaalhaigla.ee
Hemoglobinopathy conditions consist of a variety of the 
hemoglobin disorders caused by structural abnormalities 
and/or alteration in the amount of globin chains. Thalas-
semia is the most common type of hemoglobinopathy 
transmitted by heredity. Non-endemic countries such as 
Estonia, are also involved in thalassemia-related problems 
because migration from endemic to non-endemic areas is 
bound to increase. In non-endemic countries physicians 
need to know how to diagnose thalassemias and how 
to distinguish them from other causes of a microcytic 
anemia, as well as to have knowledge of treatment options 
for severe forms of thalassemia.
The basic strategy for screening of hemoglobinopa-
thies requires integration of:
• Complete blood count, reticulocytes
• Morphology of peripheral blood smear
• Iron status assays: iron, ferritin, transferrin satura-
tion, serum soluble transferrin receptor. Transferrin 
and ferritin are acute phase reactants and values may 
change in iron deficiency with coexistent inflamma-
tion or liver disease. It is best to measure them at 
the time when no acute illness is present. 
• Hemolysis parameters: bilirubin, LDH, haptoglobin 
(acute phase protein)
• Hemoglobin electrophoresis
Hemoglobin electrophoresis should be done to all 
patients with microcytic anemia who are not iron defi-
cient or who do not respond to iron replacement therapy.
The reason for referral and information on the clinical 
history and medication are required for the interpreta-
tion of results.
Screening for hemoglobinopathies is very important 
in non-endemic countries and requires focused attention. 
DNA analysis will confirm the nature of any haemoglobin 
variant.
OP-8. Relationship between clinicians 
and specialists of laboratory medicine in 
diagnostics of haemostasis disorders
Daiva Urboniene – Lithuanian University of Health 
Sciences, Lithuania; Hospital of Lithuanian University of 
Health Sciences Kauno klinikos, Kaunas, Lithuania
E–mail: daivaurboniene@yahoo.co.uk
Clinical and laboratory diagnostics have become more 
complicated compared to the diagnostics of the past. 
Haemostasis laboratories (as well as other laboratories) 
have introduced a number of new tests and modern 
technologies during the past decades.
Increase of diagnostic possibilities gives physicians 
more chance to make a wrong choice – to order inap-
propriate lab tests, to miss informative tests or to 
make wrong interpretations of correctly ordered tests. 
Undetected or ignored presence of preanalytical factors 
(omission of sampling requirements, unsuitable samples, 
ignorance or missing information about anticoagulant 
therapy, etc.) causes changes of lab test results. Spurious 
results in routine coagulation and in specialized haemo-
stasis testing could also lead to serious adverse clinical 
outcomes and undesirable economic consequences.
Laboratory specialists quite often concentrate their 
efforts on technical performance and on achievement 
of the highest quality of tests. They often tend to forget 
about the conversion of lab data into useful information 
for clinicians and for the patients.
Patient-centered outcome and economy-related prob-
lems may be solved by two sided communication between 
clinicians and lab professionals. Communication could 
help to diagnose haemostasis disorders more quickly 
and accurately, in cases with less than optimal combina-
tion of tests for improving the situation, to eliminate 
unnecessary haemostasis tests, to ensure feedback to 
physicians about their erroneous ordering practices, to 
provide information about new or less known tests, etc.
It has been reported that adverse clinical outcomes 
due to errors (or lack) in communication are more 
frequent compared to errors due to inadequate clinical 
skills. To identify the causes of poor communication 
and to find ways for improvement are consequently of 
crucial importance. In order to increase the benefit of 
laboratory testing for diagnostics, laboratory special-
ists should focus on active development of relationship 
with clinicians.
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OP-9. Critical risk results in Europe
Éva Ajzner – Task and Finish Group on Critical Results 
of the European Federation of Clinical Chemistry and 
Laboratory Medicine, Australasian Association of Clinical 
Biochemistry, Department of Laboratory Medicine 
and Clinical Microbiology, Jósa University Hospital, 
Nyíregyháza, Hungary
E-mail: ajzner@med.unideb.hu
Management of critical risk results (CRR), i.e. laboratory 
results that require immediate medical attention and 
action because they indicate a high risk of imminent 
death or major patient harm, is considered a significant 
patient safety factor. 
The Task and Finish Group on Critical Results (TFG-
CR) of the European Federation of Clinical Chemistry 
and Laboratory Medicine collected information on the 
practice of 871 European laboratories in CRR manage-
ment and analysed the ALs of almost 400 laboratories 
within the frames of an international survey in 2012. This 
presentation will discuss the observed CRR management 
practices in the light of the recommendations of the 
recently published standard in the field of CRR manage-
ment (CLSI-GP47).
The fundamental requirement of CLSI-GP47 on the 
necessity of organisational-specific ALs and CRR reporting 
policy was found to be satisfied in a vast majority of the 
participating laboratories. However, significant varia-
tions were seen between the laboratories in the aspects 
regarding how they compiled their alert lists (ALs) as well 
as regarding which tests these laboratories selected for 
inclusion in ALs. The most important nonconformities in 
the designing of ALs were the following: the thresholds 
were often not set on broad consensus at institutions; 
less than half of the laboratories reported to have set 
timeframes in reporting; and only 16% of the provided 
ALs contained indication of the different urgencies of 
notification linked to certain values. Wide variations 
were also observed in the reporting process of CRRs 
among the laboratories. Their policies were not always 
based on the patients`  clinical condition. Only a third 
of the respondents had established practices for proper 
documentation or monitoring of the performance of 
their CRR notifications. 
The findings of the European survey confirm the need 
for organising training courses on the recommendations 
of CLSI-GP47, which would help laboratory professionals 
to acquire a patient-risk based approach in AL develop-
ment and CRR management.
OP-10. New biomarkers for pregnancy 
Kaspar Ratnik1, 2, Kristiina Rull1, 3, Kalle Kisand1, Ele 
Hanson3, Maris Laan1 – 1University of Tartu, Tartu, 
Estonia, 2Synlab Eesti Ltd, Tartu, Estonia, 3Women’s 
Clinic, Tartu University Hospital, Tartu, Estonia
E-mail: maris.laan@ut.ee
Today, there are no widely accepted biomarker tests in 
clinical routine to predict the emergence of pregnancy 
complications in sufficient advance. Over tens of years, 
majority of efforts made by the scientific and clinical 
community have been targeted to prognostics of preec-
lampsia (PE), a multisystemic disorder affecting both the 
mother (extreme hypertension, proteinuria, impaired 
liver funciton etc) and the foetus (fetal growth restric-
tion (FGR), preterm birth (PTB), perinatal mortality). 
Pathophysiology of PE is complicated and novel evidence 
indicates several subtypes of PE arising for different 
causes (1, 2). As the main cause behind PE is impaired 
placental development and function, profiling of placental 
differential gene/protein expression has been extensively 
utilized to compile the list of potential biomarkers for 
PE (3, 4). Currently, two commercial companies offer 
prognostic tests for PE based on analysis of two well-
established maternal serum based biomarkers derived 
from placental malfunction, i.e. sFLT1 and PlGF (Roche 
Diagnostics, Thermo Scientific). However, these tests 
are expensive and do not have sufficient sensitivity and 
specificity for making long-term clinical decisions (5). One 
of the aims of the Happy Pregnancy (HP) project (http://
www.happypregnancy.ut.ee/ ) has been to investigate and 
discover new maternal serum biomarkers for pregnancy 
complications, and to develop clinically applicable assays 
for them. The study is executed in collaboration of the 
University of Tartu, Tartu University Hospital and the 
Synlab Eesti Ltd. (former Quattromed HTI Laboratory 
Ltd.). The development of new biomarker tests builds 
on utilization of an excessive sample collection estab-
lished within the HP project, including longitudinal 
blood and urine samples of >2000 pregnant women 
across normal and adverse pregnancy outcomes (PE, 
FGR, PTB, gestational diabetes). Based on the literature 
evidence and unpublished data, we have selected ~20 
serum biomarkers reported to be significantly altered 
in PE. In the first stage, we are developing a method 
for simultaneous detection of multiple biomarkers in 
maternal serum and for evaluating their diagnostic 
potential to predict PE. The analytical characterisation 
of the pilot assay is currently ongoing. For the perfor-
mance of two analytes, sFlt1 and PlGF, we were able to 
conduct a pilot study comparing the performance of our 
novel assay and the available commercial ELISA-based 
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assays (Thermo Scientific B·R·A·H·M·S Kryptor). The two 
assays show very good correlation regarding measure-
ments (R² > 0.93). Reference values, optimal timing of 
measurements, risk assesment and outcome prediction 
scores are in the analysis pipeline. 
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OP-11. New trends in cardiovascular 
laboratory
Kari Pulkki – Department of Clinical Chemistry, 
University of Eastern Finland and Eastern Finland 
Laboratory Centre, Kuopio, Finland
E-mail: kari.pulkki@uef.fi
The first cardiac enzymes and the main aspects of lipo-
protein metabolism were described in the 1950s and 
early 1960s. Now, there is universal definition of acute 
myocardial infarction, according to which use of high-
sensitive troponins, in association with clinical evalua-
tion and ECG for diagnosis is recommended. There are 
several troponin I/T-assays, which fulfil the criteria for 
high-sensitive troponin measurements. Today, a change 
in troponin levels (delta) is needed to show acute cardio-
myocyte injury (0 and more than 3 hours). Also shorter 
protocols (1 hr and 2 hr) are studied and applied. With 
the application of high-sensitive Tns in two samples, 
there is less clinical need for other early markers (FABP, 
copeptin etc.), except in rule-out protocols. The CK-MB 
may be used for diagnosis of AMI in association with 
heart-operations (CABG or PCI). The POCT for Tns is 
demanding as the methods are analytically less sensitive 
than automated methods in core labs. In a regional health 
care system with common guidelines, the use of several 
markers and/or several cut-offs for rule-in or rule-out is 
also challenging. The use of natriuretic peptides is recom-
mended as one of the tools for diagnosis of acute heart 
failure, if available. There are evidence-based rule-out and 
rule-in cut-off values for both N-ProBNP and BNP. New 
markers for heart failure are available and are evaluated 
for clinical use. The most promising new markers are 
GDF-15, galectin-3 and ST2. Based on recent studies they 
all are associated with chronic heart failure, complica-
tions and remodelling of the heart. Routine assays for 
the clinical laboratory will be available. Evaluation of 
cardiovascular risk is based on risk scores (including 
lipid profile). Apolipoproteins as risk markers have been 
studied for several decades. In some countries, apoB, 
instead of LDL, is recommended for clinical practice. 
There is also a current joint consensus statement by EAS 
and EFLM, which supports the use of non-fasting blood 
samples for routine testing, including the lipid profile. 
The corresponding applications are discussed.
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OP-12. Biomarkers in chronic kidney disease 
Erika Skrodeniene1, Vaida Petrauskiene2, Inga Arune 
Bumblyte2, Vytautas Kuzminskis2, Astra 
Vitkauskiene1 – 1Department of Laboratory Medicine, 
Lithuanian University of Health Sciences, Medical 
Academy, Kaunas, Lithuania; 2Department of 
Nephrology, Lithuanian University of Health Sciences, 
Medical Academy, Kaunas, Lithuania
E–mail: erika.skrodeniene@kaunoklinikos.lt
OBJECTIVES. Chronic kidney disease (CKD) is one of 
the leading public health problems. Cardiovascular 
diseases (CVD) account for 50% of all deaths in the CKD 
setting. Vascular calcification contributes significantly 
to higher mortality among this population. Disorders 
of Ca-P metabolism were regarded for many years as a 
major factor contributing to high cardiovascular risk 
in CKD patients. Proteinuria, especially together with 
eGFR, is a sensitive marker for progression of CKD but 
it has some limitations. Discovery of novel biomarkers 
changes the understanding of the pathogenesis of both 
progressions of CKD and CVD risk.
The aim of our study was to evaluate the levels of 
Human Fibroblast Growth Factor 23 (FGF23) and Matrix 
Gla Protein (MGP) in hemodialysis (HD) patients and 
assess its possible links with cardiovascular diseases 
and mortality.
METHODS. The study included 81 HD patients (44 men 
(54.3%) and 37 women (45.7%)) treated at the HD unit 
of Hospital of Lithuanian University of Health Sciences 
Kauno klinikos. Clinical data, FGF23, inactive form MGP 
and other laboratory data were analysed.
RESULTS. The mean age of patients was 60.9 ± 16.01 
years (22–86) and the mean HD vintage was 39.26 ± 46.24 
months (1–182). The duration of HD of 52 patients (64.2%) 
was more than a year, 17 patients (21%) were diabetic, 
42 patients (51.9%) had cardiovascular diseases. During 
the follow-up period, 17 (20.9%) patients died.
Levels of MGP were significantly higher for patients 
who survived after 2 years of follow-up compared to 
patients who died (2.05 ± 1.42 vs. 1.38 ± 0.53 ng/ml, p 
= 0.003). Positive correlation was found between FGF23 
and MGP (r = 0.76, p < 0.001).
CONCLUSION. According to our findings, hemodi-
alysis patients with 2 -year survival had higher MGP 
values. These values and the unexpected findings of the 
positive correlation between FGF23 and MGP allowed to 
suggest that these novel biomarkers may play a role in the 
pathogenesis of cardiovascular diseases in hemodialysis 
patients. However, these findings require further research.
OP-13. New biomarkers of articular cartilage 
in patients with osteoarthritis
Agu Tamm – Department of Laboratory Medicine, 
University of Tartu, Tartu, Estonia
E–mail: agu.tamm@kliinikum.ee
BACKGROUND. Diagnosis of OA is based on clinical symp-
toms and radiological findings. How-ever, usually the 
latter describe already the advanced stage of the disease. 
Using biomarkers (BMs), it is expected to discover even 
the pre-radiographic disease, before the clinical illness. 
When investigating BMs one has to distinguish the two 
main radiogaphic features: osteophytes (OPH) and joint 
space narrowing ( JSN).
METHODS. This report presents the findings of three 
biomarkers of knee OA:(1).Urinary type II collagen frag-
ment (uC2C) reflecting cartilage degradation, ( EIA) using 
a monoclonal AB that recognizes the carboxyl  terminus 
of the 3/4 in the degraded alpha1(II) chain; (2). Cartilage 
Intermediate Layer Protein (sCILP)-2 in serum, assessed 
by an in-house competitive immunoassay, AnaMar AB, 
Sweden. The assay detects the C-terminal part of CILP-2 
domain1 with polyclonal goat anti-CILP2 AB; (3). Cartilage 
oligimeric protein (sCOMP) reflecting general turnover of 
cartilage as well as othter joint tissues (commercial ELISA). 
The BMs were applied in the early phase of knee OA in a 
middle-aged cohort and relevant controls (36–62, mean 
age 50) both at baseline and after 3 years. Tibiofemoral 
(TF) and patellofemoral (PF) radiographs were graded 
for presence of OA.
RESULTS. Two BMs were able to distinguish OA patients 
with grade 2-3 and without structural changes. The COMP 
values were increased in patients with „progresssive“ 
knee OA. After 3 years all three BMs showed stronger 
correlations with OPH compared with JSW. Unlike the 
other biomarkers, CILP-2 showed a decrease in patients 
with early grade of OA. In knee arthroscopy-detected 
cartilage lesions, a decrease of CILP2 was found already 
in grade 1 and an increase of uC2C, in grade 2. 
CONCLUSIONS. *Longitudinal investigation of patients 
with definite forms of OA demonstrated that increased 
values of uC2C and decreased values of CILP2 could be 
associated with knee cartilage lesion, and progression 
of OA.*Cartilage neoepitopes offer new opportunities for 
in-depth investigation of the knee cartilage.
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OP-14. Patient-focused laboratory medicine. 
Lab4Patients Horizon 2020 project
Wytze P. Oosterhuis – Zuyderland Medical Center, 
Department of Clinical Chemistry and Haematology, 
Heerlen, The Netherlands; EFLM Working Group of 
Patient Focused Laboratory Medicine
E-mail: w.oosterhuis@atriummc.nl
There is growing demand that patients be better 
informed and participate more actively in treatment 
related decisions. Initiatives to provide patients with 
access to their data, such as patient portals, ref lect a 
patient-driven approach. The better informed patient is 
better equipped for participating in the medical decision 
process, and the terms patient empowerment and shared 
decision making are often used in this context. It has 
been shown that more active involvement of patients 
will lead to improved motivation to adhere to treat-
ment, with a better health outcome. Many physicians 
are concerned that record access will bring about more 
work, with extra consultations and telephone calls as a 
result of patient misunderstanding. Studies suggest the 
opposite – that record access can reduce the demand for 
resource. Both the European Federation of Clinical Chem-
istry and Laboratory Medicine (EFLM) and the Section 
of Laboratory Medicine of the UEMS (Union Européenne 
des Médecins Spécialistes) recognize the development 
of patient empowerment and the changing role of care 
providers and patients. To this end, the EFLM has estab-
lished the Working Group Patient Focused Laboratory 
Medicine, that took the initiative of the current project. 
The overall aim of the project is to design, develop 
and evaluate an interpretative knowledge and reporting 
system that will inform patients so that they can compre-
hend the significance of their laboratory test results, 
enabling them to better participate in the shared deci-
sion process with their physician. The system described 
in the Lab4Patients project represents a new integrated 
approach to process the data from other healthcare 
systems and communicate the results in a flexible way to 
different receiving systems and individual using several 
advanced types of communication.
The project is recently submitted; when accepted 
by the EC in Brussels it will help to reach a European 
standard in the translation of laboratory test information 
to information understandable for patients.
OP-15. Syndrome based test panels in hospital 
laboratory
Karel Tomberg – Laboratory, North Estonia Medical 
Centre, Tallinn, Estonia
E–mail: Karel.Tomberg@regionaalhaigla.ee
Different tools have been proposed to help clinical 
doctors in laboratory test requesting. At our hospital we 
developed syndrome based test panels in cooperation 
between clinical and laboratory doctors. 
The panels were included in a computerised physician 
order entry (CPOE) system. For each panel, a pre-defined 
and optional set of tests was created. Requesting can be 
performed in one button click or tests can be added or 
removed in case of need. 
Altogether 16 test panels were developed, 6 panels for 
the use at the hospital and 10 specifically for the Dept 
of Emergency Medicine (EM). In EM, test panels were 
designed for some of the most frequent acute clinical 
syndromes which included abdominal pain, shortness 
of breath, chest pain, monitoring myocardial markers, 
cerebral infarction with indication of thrombolysis, 
polytrauma, sepsis, chronic anaemia, urinary tract infec-
tion and joint pain. 
At the hospital, test panels were implemented for 
cardiovascular risk assessment (atherosclerosis), venous 
thrombosis, antiphospholipid syndrome, contact case 
with patient’s blood or body fluids, monitoring of clinical 
nutrition, and diagnosing malaria. 
Syndrome based test panels help to save clinicians’ 
time in a busy working environment and to avoid omitting 
of necessary tests in typical situations. Joint collabora-
tion with clinical doctors enable better to introduce the 
test menu of the laboratory and to implement diagnostic 
guidelines.
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OP-16. Comparative whole genome 
hybridisation methods in molecular 
diagnostics
Beata Aleksiūnienė1, 2, Laima Ambrozaitytė1, 2, Algirdas 
Utkus1,2 – 1Centre for Medical Genetics Vilnius University 
Hospital Santariškių Klinikos, Vilnius, Lithuania; 
2Department of Human and Medical Genetics, Faculty of 
Medicine, Vilnius University, Vilnius, Lithuania
E-mail: beata.aleksiuniene@santa.lt
OBJECTIVE. Comparative whole genome hybridisation 
(CGH) is currently the first-tier genetic diagnostic test 
for the detection of chromosomal imbalances in patients 
with congenital heart defects (CHD). The CHD as the 
most common congenital anomaly (approximately 1 
in 100 newborns) has been reported to be frequently 
associated with pathogenic copy number variants (CNVs). 
Recently, CGH has been successfully applied to identify 
CNVs in postnatal and prenatal patients with CHD. This 
study aims to identify genomic imbalances in patients 
with syndromic and nonsyndromic CHD.
METHODS. Single nucleotide polymorphism CGH 
testing (HumanCytoSNP-12v2.1, Illumina) was carried 
out in 30 patients with syndromic and nonsyndromic 
CHD of unknown etiology, including 28 postnatal and 2 
prenatal referrals. The testing is currently ongoing for 
other samples. 
RESULTS. There were 8 clinical signif icant copy 
number variants identif ied in 7 patients. A ll these 
patients had additional phenotypic anomalies and/or 
intellectual disability. These CNVs included three de novo 
deletions, one deletion inherited from mother, one de 
novo duplication and three of yet unknown inheritance 
mode. Four of the pathogenic CNVs overlapped with 
known microdeletion / microduplication syndromes. No 
significant CNVs were detected in patients with isolated 
nonsyndromic CHD.
CONCLUSIONS. Our initial results contribute to the 
evidence that CGH has a high diagnostic yield and value 
for improved genetic counselling.
OP-17. Management of sepsis in Estonian 
hospitals 2013-2014
Pille Märtin – Infection Control Department, West-
Tallinn Central Hospital, Tallinn, Estonia
E-mail: pille.martin@keskhaigla.ee
Sepsis is widely defined as a systemic inf lammatory 
response to an infectious disease, caused by viruses, 
bacteria, fungi and protozoans. Sepsis, severe sepsis and 
septic shock are an important public health problem 
requiring urgent action and substantial human and 
material resources.
Prevalence rates of sepsis are estimated to be 30.7 
million cases per year, in addition, 23.8 million severe 
sepsis cases. Nearly 6 million people die every year. The 
mortality rate of sepsis is 6.7%, it is higher in severe 
sepsis (20.7%) and the highest in septic shock (45.7%) 
(1). International guidelines for management of severe 
sepsis and septic shock (Surviving Sepsis Campaign) 
have been revised several times, most recently in 2012.
Estonia introduced national guidelines in 2009. These 
guidelines were approved by the Estonian Society of 
Internal Medicine, the Association of Surgeons of Estonia 
and the Estonian Society for Infectious Diseases. They 
were also approved by the Estonian Health Insurance 
Fund on 17.06.2010.
It is important to recognize sepsis because empirical 
antibiotic therapy should be started as soon as possible, 
within 1 hour. Although sampling should not delay timely 
administration of antimicrobial agents in patients with 
severe sepsis, obtaining appropriate cultures before 
administration of antimicrobials is essential to confirm 
infection and responsible pathogens and to a l low 
de-escalation of antimicrobial therapy after receipt of 
the susceptibility profile. The Estonian Health Insurance 
Fund regularly examines the quality of services and the 
need for them, incl. approved guidelines. Management 
of sepsis at Estonian hospitals according to the national 
guidelines was the subject of audit in 2013–2014. 
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OP-18. Mass-spectrometry for bloodstream 
pathogen identification in routine practice
Marina Ivanova, Valentina Kolesnikova, Linda Pirožkova, 
Anastasia Pavelkovich – East-Tallinn Central Hospital 
Laboratory, Tallinn, Estonia
E-mail: marina.ivanova@itk.ee
INTRODUCTION. In the case of suspicion of sepsis, rapid 
identification of bloodstream pathogen is essential to 
start adequate antibiotic therapy. In comparison with 
the conventional diagnostic procedure, application of 
mass spectrometry allows identification of a pathogen 
one day earlier.
OBJECTIVE. To describe the usage of MALDI-TOF 
Mass Spectrometry in November and December 2015 at 
the East Tallinn Central Hospital, and to compare the 
results of conventional culture and mass spectrometry 
methods for identification of bloodstream pathogens.
METHODS. Blood collected from patients with clinical 
suspicion of sepsis was first analysed using the blood 
culture (BC) system. From among positive BC bottles, one 
bottle per patient-episode (cases where BC was collected 
from the same patient at time points more than a week 
apart were regarded as separate patient-episodes) was 
processed using both the conventional culture and MALDI 
Sepsityper methods. 
RESULTS. A total of 775 BC bottles (379 sets) from 
216 patients were analysed with BC system, resulting in 
90 positive bottles. At least one bottle was positive in 54 
of 240 patient-episodes (23%); 53 bottles were processed 
further. According to the conventional culture, one 
pathogen was identified in 50, and two pathogens were 
identified in 3 cases. MALDI Sepsityper failed to identify 
any pathogens in 8 bottles of 53 processed (15%). In the 
remaining 45 cases, MALDI Sepsityper identified one 
pathogen. The pathogen was the same as identified by 
the conventional method in 43 bottles (81%); in 2 cases 
MALDI Sepsityper identified one of the two pathogens 
that had been demonstrated as being present by the 
conventional culture.
CONCLUSIONS. Mass spectrometry is a powerful 
method to speed up the ethiological diagnosis of sepsis 
in the routine practice of a microbiology laboratory. In 
our study, 43 of the 240 patient-episodes of clinically 
suspected sepsis (18% of all; 80% of all BC system posi-
tives), the pathogen was identified by MALDI Sepsityper 
one day earlier compared with the conventional culture. 
OP-19. Diagnostic possibilities of fungal 
infections
Helle Järv1, Piret Mitt2, Anne Kallaste2, Vivika Adamson2 – 
1United Laboratories, Tartu University Hospital, Tartu, 
Estonia, 2Department of Infection Control, Tartu 
University Hospital, Tartu, Estonia
E-mail: helle.jarv@kliinikum.ee
OBJECTIVES. Invasive fungal infections remain one of 
the most severe complications in immunocompromised 
patients. Early, sensitive and reliable diagnosis is manda-
tory. Clinical signs and symptoms of fungal infection 
are non-specific. Non-invasive diagnostic procedures are 
preferable because often patients are unable to undergo 
invasive diagnostic procedures. This study characterizes 
the current situation of diagnostic methods regarding 
the use and incidence of invasive candidiasis diagnosed 
in Estonia.
METHODS. The statistics of diagnosed cases of inva-
sive candidiasis, invasive aspergillosis, mucormycosis and 
cryptoccosis in different patient groups, based on the 
data of the Estonian Health Insurance Fund database, 
is presented for a 5-year period (2010–2015). Antifungal 
susceptibility data about candidemia were collected from 
the records of Tartu University Hospital. A question-
naire on the diagnostic methods used at microbiology 
laboratories was sent in 2000 and 2015, development of 
diagnostic methods is compared.
RESULTS. The blood culture still remains the main 
diagnostic tool for invasive candidiasis. The practice 
of performing blood cultures has improved over the 
15 year period. Screening for circulating antigens like 
galactomannan or other polysaccharides has been proved 
to be beneficial in preventing the severe stage of fungal 
infection. Centralized laboratory service has allowed to 
use more diagnostic tests and a complicated diagnostic 
approach in case of rare infections.   
CONCLUSIONS. The results highlight the need to 
apply novel immunological and molecular methods at 
least at regional hospitals.  
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OP-20. Standardization of laboratory tests in 
Lithuania
Dalius Vitkus – Department of Physiology, Biochemistry, 
Microbiology and Laboratory Medicine, Vilnius 
University, Vilnius, Lithuania; Lithuanian Society of 
Laboratory Medicine, Vilnius, Lithuania
E-mail: dalius.vitkus@santa.lt
OBJECTIVES. The aim of the presentation was to describe 
the current situation in the standardization of laboratory 
tests at Lithuanian laboratories and health care institu-
tions. The need for standardization was recognized by 
several e-Health project groups whose aim was setting-
up of common platforms for ordering laboratory tests 
by healthcare professionals of different institutions and 
for pooling lab tests results so that they would be avail-
able for use irrespective of where a test was performed. 
METHODS. A group of laboratory professionals from 
all subspecialties of laboratory medicine has been estab-
lished by the Board of Lithuanian Society of Laboratory 
Medicine. The LOINC nomenclature was selected as a 
general background for compiling a list of tests and meas-
urement procedures most commonly used by local labs.
RESULTS. It was identified that the LOINC nomencla-
ture was too complex for many small labs and primary 
health care providers; also the national laboratory system 
has different traditions for grouping, ordering tests and 
reporting results. Laboratory tests were divided into 8 
groups according to the main subspecialties of laboratory 
medicine and a unique coding system was established. 
Only the measurement procedures recommended by 
standards and by internationally recognized organizations 
(IFCC, CLSI, etc.) were included with the aim to prove 
the situation where out-of-date testing principles with 
limited specificity or sensitivity are still widely used. 
It was later recognized that very strict methodological 
limitations can be very inconvenient for labs and can 
lead to an abrupt increase of costs. Therefore, in the 
case of some test methods, which are not up-to-date, a 
reasonable transition period with an annual revision of 
the nomenclature was foreseen.  
CONCLUSIONS. The developed nomenclature will 
improve laboratory services for patients and health care 
providers through standardization of laboratory tests 
and methods as well as will simplify communication 
between the e-Health subsystems.
OP-21. LIS and eHealth in Finland
Hannu Honkala – Mylab Oy, Tampere, Finland
E-mail: hannu.honkala@mylab.fi
Along with the evolution of eHealth also the Laboratory 
Information Systems is in the middle of a significant 
change. General eHealth drivers: cost of care, ease of 
use and faster decision-making set the pace also for 
LIS development. The borders between digital health 
services are disappearing, which changes the health care 
processes supported by seamless and timely integration 
of information from various sources – including labora-
tory diagnostics. Furthermore, the processes inside the 
laboratory diagnostics are getting closely integrated 
and all this is efficiently supported by integrated LIS 
implementation. 
Health care IT in Finland is facing great changes: huge 
public EHR projects are being planned. Interoperability, 
integration and transfer of information play the key role 
in embracing new customer-oriented eHealth solutions. 
Also the interest of the government in eHealth is more 
pronounced. An example of this is the central storage 
of health data (Kanta) integrating data from public and 
private EHRs, to be used by consumers and professionals. 
The basic function of the LIS, from the point of view 
of the clinician, has been rather simple: getting orders 
and delivering results. Both of these ends have started 
to become much richer. We can add intelligence to both 
clinical and lab resource management, provide more 
information beyond plain results and support medical 
decision-making. All this is becoming available for the 
consumers as well. Self-service appointments and access 
to own lab results are examples of this development. 
This trend of professional and consumer experiences is 
moving closer to each other, consumerization, has truly 
reached health care as well: professional services are 
getting commoditized, consumers are getting self-service 
access to professional information and consumer-style 
approaches are re-shaping professional usage. Services 
are mobile, they are web based and developing fast. 
Costs are indeed decreasing, usage is easier and decision 
making faster. 
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OP-22. Interpretation of syphilis 
serodiagnostic tests: looking from the 
clinician`s side
Peter Karl Kohl, Agnieszka Beata Servin, Bozsena 
Chodynicka – Department of Dermatology and 
Venereology, Vivantes Klinikum, Berlin-South, Germany; 
Medical Academy of Bialystok, Bialystok, Poland 
E-mail: Peter.Kohl@vivantes.de
OBJECTIVES. The subject of this presentation is the 
knowledge of currently used serologic tests for syphilis, 
and of an ideal serologic test for syphilis, and comparison 
of current syphilis serology tests.
METHODS. We describe limitations in interpreta-
tion of syphilis serology results and the consequences 
of suboptimal values of serology tests; also how false 
results of non-treponemal and treponemal tests come 
into being and why a two-test diagnostic approach for 
the serodiagnosis of syphilis is necessary.
RESULTS. The enzyme linked immunospot assay for 
treponema pallidum specific antibody secreting cells 
and the line immuno assay represent new diagnostic 
possibilities of syphilis serology.
CONCLUSIONS. It is evident that one has to take 
account of limitations in the interpretation of syphilis 
serology. These limitations comprise the suboptimal sensi-
tivity and specificity of the complex immune response 
of the host to Treponema pallidum, the passive transfer 
of anti-treponemal IgG antibodies through the blood-
brain barrier and the placenta and the abnormalities of 
serological response to Treponema pallidum in immune 
deficiency patients. Further developments, molecular 
biology techniques, standardisation and automation, will 
contribute to more simple and more precise interpreta-
tion of syphilis serology.
OP-23. Application of syphilis laboratory 
diagnostics in Latvia
Gatis Pakarna, Aija Gulbe, Jeļena Storoženko, Sanita 
Kuzmane, Baiba Rozentāle – Riga East University 
Hospital, Latvian Center of Infectious Diseases, Riga, 
Latvia
E-mail: gatis.pakarna@aslimnica.lv
OBJECTIVES. Serological tests are the mainstay in 
the diagnosis and follow up of syphilis. Detection of 
Treponema pallidum by the dark-field microscope or 
PCR is suitable for lesion exudates or tissue. Guidelines 
contain recommendations for the laboratory diagnosis 
of syphilis. For syphilis serological diagnostics, tests are 
used according to the 2014 European Guidelines in the 
Management of Syphilis. The aim of this study was to 
follow up guidelines of syphilis serological diagnostics 
in Latvia.
METHODS. From 2013 to 2014 there were tested 9650 
samples at the laboratory of Latvian Center of Infectious 
diseases. We used syphilis serological tests such ELISA 
(Abbott diagnostics, USA; Mikrogen diagnostic, Germany), 
TPHA (newMarket Laboratories, United Kingdom), IFAabs 
(bioMerieux, France), IB (Mikrogen diagnostic, Germany) 
and RPR (Lab21 Healthcare, United Kingdom).
RESULTS. For syphilis screening, we used ELISA test. 
Altogether 9650 samples were tested by ELISA, among 
them the number of positive samples was 1032. ELISA 
positive samples were re-tested using TPHA. A total of 
979 samples were TPHA positive, coincidence between 
the ELISA and TPHA was 94.8%. Fifty- three TPHA nega-
tive and ELISA positive samples were tested using IFA 
or IB in case clinicians ordered testing. We performed 
ELISA IgM, in case there were suspicious cases of early 
syphilis. Dermatovenerologists ordered both RPR and 
ELISA in cases of suspected of very early syphilis.
CONCLUSIONS. Laboratory serological diagnostics of 
syphilis is based on the 2014 European Guidelines on the 
Management of Syphilis. Treponemal ELISA has become 
the test of the first choice for syphilis screening. Labo-
ratories should collaborate with dermatovenerologists 
in serological testing of syphilis.
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OP-24. Sexually transmitted infections in 
Lithuania
Vesta Kucinskiene1, Simona Sabulyte1, Vijoleta 
Juseviciute2, Astra Vitkauskiene2 – 1Department of 
Skin and Venereal Diseases, 2Department of Laboratory 
Medicine, Lithuanian University of Health Sciences, 
Kaunas, Lithuania
E-mail: vesta.kucinskiene@gmail.com
In Lithuania there are three notifiable bacterial sexu-
ally transmitted infections (syphilis, gonorrhoeae and 
chlamydial infection) and one viral (HIV). The STIs are 
diagnosed and managed following the recommenda-
tions of IUSTI guidelines and reported if a person meets 
clinical, laboratory and epidemiological criteria. Labo-
ratory criteria are crucial for notifiable STIs. The main 
routine laboratory tests such as microscopy of genital 
smears, serology for syphilis (RPR, TPHA), serology for 
HIV are available in the laboratories of bigger hospitals 
or even primary health centers. Laboratory tests for 
complicated STIs (e.g. VDRL-CSF for neurosyphilis, TP 
IgM antibodies for congenital syphilis, PCR for congenital 
herpes infection) as well as antibiotic resistance control 
are concentrated at the laboratories of the university 
hospitals and National Public Health Surveillance Labo-
ratory (NVSPL). Different molecular tests for Chlamydia 
trachomatis, Neisseria gonorrhoeae, Trichomona vaginalis, 
Mycoplasma genitalium, ureoplasmas are introduced in 
university hospitals, NVSPL and private laboratories. 
Nucleic acid amplification tests for STIs are not covered 
by health insurance and the patients have to pay for them.
The incidence rates over the last 3 years (2012–2014) 
for syphilis ranged from 7.6 to 8.8 cases/100000 popu-
lation, for gonococcal infection, from 7.3 to 5.6 cases, 
and for chlamydial infection, from 8.9 to 15.3 cases. In 
recent years several epidemiological projects on STIs 
in Kaunas have shown that young people actively seek 
for timely STIs testing and treatment. In 2013 at the 
Hospital of Lithuanian University of Health Sciences, 
a cross sectional study was designed. The participants 
completed a standardized questionnaire. First voided 
urine (FUV) samples were analysed for the presence of 
7 urogenital pathogens: Chlamydia trachomatis, Neisseria 
gonorrhoeae, Trichomonasvaginalis, Mycoplasma hominis, 
Mycoplasma genitalium, Ureaplasma urealyticum, Urea-
plasma parvum by using the multiplex real-time PCR assay 
“Anyplex TM II STI-7 Detection” (Seegene, Inc., Seoul, 
Korea). The results showed that the frequency of STIs 
among 963 patients was: 6.2% for chlamydial and 0.4% for 
gonococcal infections, 2.7% for Mycoplasma genitalium 
and 0.5% for Trichomona vaginalis infections. In the age 
group 20–30 years C. trachomatis was detected in 10.2% 
of women, in the younger than 20 years age group, in 
6.25%, and in the age group of 30–40 years, in 4.69% of 
women. Chlamydia trachomatis was more common among 
women who had more than two sexual partners in the 
last half-year. Most of the infected persons did not want 
to give information about their sexual relationship with 
other partners.
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OP-25. Lymphocyte subsets and serological 
markers in melanoma patients treated with 
ECHO7 virus
Simona Donina1, 2, Elina Ozola2, Margarita Citovica1, 
Ludmila Engele1 – 1Riga East University Hospital, 2Riga 
Stradiņš University, Riga, Latvia
E-mail: donsimon@inbox.lv
OBJECTIVE. To evaluate changes in immunbiological 
markers during one year of virotherapy and recurrence 
or metastases in patients who have undergone radical 
melanoma excision and have received treatment with 
ECHO-7 virus Rigvir. 
METHODS. 70 patients with skin melanoma stage IB 
and II who had undergone radical melanoma excision 
at the REUH Oncology Centre of Latvia in 2012 were 
analyzed. The CD3+, CD3+4+, CD3+8+, CD16+56+, CD19+, 
CD38+, CD95+ cells, S100 and LDH were evaluated in 
peripheral blood (PB) and T subsets were evaluated in 
tumour tissue. Ly subsets were determined before starting 
the therapy and at 1, 3, 6, 9 and 12 months during the 
therapy. Statistical analysis of the data was carried out 
using the SPSS statistical software (V.20).
RESULTS. The incidence rate of metastases or disease 
recurrence in patients who received Rigvir was 21.4%, while 
in the control group it was 30.1% during the three years 
of follow-up. Sensitivity of S100 and LDH increased with 
the progression of the disease in visceral organs. After 1 
month of Rigvir therapy an increase of CD16+, CD19+ and 
CD38+ and CD95+ cells was observed most often (46.2% and 
61.5% of cases, respectively). After 3months of treatment 
52.9% of the patients showed increased CD19+ and CD38+ 
cell count in PB. 6 months after the initiation of treatment 
CD4+Ly count was increased in 66.7% of cases, CD8+Ly count 
in 73.3%, CD19+Ly count in 68.8%, and CD19+Ly count in 
75% of the cases.  e cell count that expresses activation 
markers CD38+ and CD95+ had increased in 75% and 68.8% 
of the patients, respectively. After 9 months of treatment, 
CD16+ and CD19+ cell count had increased in 47.7% and 
58.8% of the cases, but after the ﬁ rst year of treatment CD8+ 
and CD19+ cell count had increased in 58.3% of all cases. 
CONCLUSIONS. The majority of patients who received 
Rigvir therapy showed an increase in the number and 
activity of T Ly subpopulations and an increase in B Ly and 
NK 6 months after the initiation of treatment, indicating 
marked activation of cellular immunity. The patients 
who were treated with ECHO 7 virus Rigvir were found 
to have less often recurrence or metastases, compared 
to patients who were followed up by observation. 
OP-26. Colorectal cancer, new immunotherapy
Jüri Laasik – Cellin Technologies LLC, Tallinn, Estonia
E-mail: juri.laasik@cellintechnologies.com
Colorectal cancer (CRC) is the fourth most common 
cause of cancer death after lung, liver and  stomach 
cancer. If CRC metastasises, and the chances of radical 
surgery are eliminated, the prognosis is poor. In 2004 the 
company DanDrit Biotech* launched a study (Colorectal 
Cancer Trial) to evaluate the clinical and immunological 
effects of treating patients with disseminated CRC using 
a dendritic cell based cancer vaccine (MelCancerVac).
MelCancerVac® (MCV) was developed as a personal-
ized medicinal product by DanDrit Biotech, for treatment 
of advanced CRC. According to European regulation 
1394/2007 (article 17), MCV is expected to belong to 
the category of cell-based medicinal products and could 
be considered an Advanced Therapy Medicinal product 
(ATMP) candidate. MCV is produced for a Phase IIB/III 
clinical trial and for Patient Name Use program by Cellin 
Technologies LLC** (Tallinn, Estonia). 
MCV is a polyvalent vaccine targeting shared tumour-
specific antigens. MCV uses patient’s own dendritic 
cells loaded with tumour antigens from the lysate of a 
specifically selected melanoma cell line. A melanoma cell 
lysate (MCL) is used as a source of tumour antigens. The 
melanoma cell line used to generate the MCL was selected 
because it expresses a well characterized family of shared 
tumour specific antigens, the MAGE-A genes. The MAGE-A 
genes have been extensively studied and are among the 
best-characterized tumour antigens. This family of genes 
is expressed in many different types of cancer, making 
them an attractive target for immune therapy.
*) DanDrit Biotech USA, Inc. is a biotech company, founded in 2001, 
focusing on clinical development of dendritic cells vaccine for 
treatment of colorectal cancer, which is ready for phase III clinical 
trials. 
**) Cellin Technologies LLC is a cell therapy products contract 
manufacturing company founded in 2008. They hold a manufacturer’s 
authorisation for preparing sterile products and an activity licence for 
handling cells, tissues and organs, issued by the Estonian State Agency 
of Medicines (SAM). 
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OP-27. Emergence and spread of antibiotic 
resistance – not only a medical problem
Tanel Tenson – Institute of Technology, University of 
Tartu, Tartu, Estonia
E–mail: tanel.tenson@ut.ee
Antibiotics are not only used in human medicine. In fact, 
more than half of the amount of antibiotics produced 
is used in animal husbandry and veterinary practice. 
Thereby, antibiotic resistance can emerge both in 
medicine and animal husbandry. Resistant bacteria and 
resistance genes can be transferred between different 
settings. The surrounding environment often provides 
here an important link. Our aim was to compare the 
bacterial strains isolated from these settings and thereby 
to identify potential routes for transfer of resistance. 
Pseudomonas aeruginosa, Escherichia coli, Staphylo-
coccus aureus and Enterococcus strains were collected 
and characterized by full genome sequencing. In many 
cases very similar bacterial strains were isolated from 
humans, animals and the environment suggesting effi-
cient transfer routes. 
The data will be discussed in the context of obser-
vations from other countries and the benefits of whole 
genome sequencing of bacterial strains will be underlined.
OP-28. Epidemiology of AB resistant gram-
negative bacteria in the Baltic Sea region
Anastasia Pavelkovich, Marina Ivanova, Siiri Kõljalg, Paul 
Naaber, Kristiine Pai, Epp Sepp, BEEp reserach team – 
Department of Microbiology, University of Tartu, Tartu, 
Estonia
E-mail: anastasia.pavelkovich@itk.ee
INTRODUCTION. The recent EARS-Net report shows that 
there is a general Europe-wide increase of antimicro-
bial resistance in the gram-negative pathogens such as 
Escherichia coli and Klebsiella pneumoniae. Production of 
extended-spectrum beta-lactamases (ESBLs) is one of the 
most common resistance mechanisms of gram-negative 
bacteria. Within the Baltic ESBL Epidemiology project 
(BEEp) ESBL positive E. coli and K. pneumoniae clinically 
relevant isolates were collected in Estonia, Latvia, Lithu-
ania, Norway and the Saint Petersburg region in Russia.
OBJECTIVE. To describe the prevalence of ESBL 
producing isolates and to determine the molecular 
epidemiology of ESBL positive E. coli and K. pneumoniae 
in the Baltic Sea region. Investigations of spreading of 
some successful clones between institutions and coun-
tries were applied.
METHODS. Clinically relevant isolates collected during 
January–May 2012 in the Baltic countries, Norway and 
Saint Petersburg were analysed. Molecular techniques 
(PCR, RT PCR, whole genome sequencing), MALDI-ToF 
typing and statistical methods were applied to the data.
RESULTS. A total of more than 13000 isolets were 
screened and 1047 were confirmed as ESBL positive. The 
ESBLA phenotype among E. coli was the most prevalent 
(n = 362/471) with 77% and was followed by strains with 
both phenotypes (ESBLA and ESBLM) (n = 69/471) at 15% 
and ESBLM (n = 40/471) at 8%. The ESBLCARBA phenotype 
was confirmed at 2.6% of K. pneumoniae isolates (n = 
15/576) with carrying blaNDM gene. There was found high 
prevalence of CTX-M-15 followed by CTX-M-14 in E. coli and 
CTX-M-15 followed by CTX-M-1 in K. pneumoniae isolates.
CONCLUSION. This study demonstrated the possible 
affection of the Baltic countries, Norway and the St. 
Petersburg area by the global ESBLs pandemic. Our 
study showed the high prevalence of CTX-M group genes 
in different combinations within group and with other 
genes in clinical E. coli and K. pneumoniae strains from 
Estonia, Latvia, Lithuania, Norway and Saint Petersburg.
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OP-29. Management of antibiotic resistance at 
the largest university hospital of Lithuania
Asta Dambrauskiene – Department of Laboratory 
Medicine, Medical Academy, Lithuanian University of 
Health Sciences, Kaunas, Lithuania
E-mail: dambrauskienea@gmail.com
The increasing rates of multidrug resistant microorgan-
isms (MDRO) make options for treating patients with 
these infections extremely limited. Increased length 
of stay, costs, and mortality have also been associated 
with MDRO. The recommended control interventions to 
reduce the rates of MDRO include administrative support, 
rational use of antimicrobials, surveillance (routine and 
enhanced), Standard and Contact Precautions, environ-
mental measures, education and decolonization.
ADMINISTRATIVE SUPPORT. Documents and commit-
tees for regulating control interventions in hospitals.
EDUCATION. Educational campaigns to enhance 
adherence to hand hygiene practices in conjunction with 
other control measures have been associated temporally 
with decreases in multidrug resistant microorganisms`  
transmission in various healthcare settings,
Rational use of antimicrobial agents. Strategies for 
inf luencing antimicrobial prescribing patterns within 
healthcare faci l it ies include education; formulary 
restriction; prior-approval programmes, including pre-
approved indications; automatic stop orders; academic 
interventions to counteract pharmaceutical influences 
on prescribing patterns, antimicrobial cycling, computer-
assisted management programmes and active efforts to 
remove redundant antimicrobial combinations. 
MDRO SURVEILLANCE. The simplest form of MDRO 
surveil lance is monitoring of cl inical microbiology 
isolates resulting from tests ordered as part of routine 
clinical care, MDRO infection rates, molecular typing 
of MDRO isolates, surveillance for MDROs by detecting 
asymptomatic colonization.
INFECTION CONTROL PRECAUTIONS. Contact precau-
tion and cohorting and other MDRO control strategies.
ENVIRONMENTAL MEASURES. Need for environ-
mental cultures. Methods for evaluation the quality of 
environmental cleaning practices.
Decolonization.
OP-30. PCR-based identification and 
serotyping of streptococcus pneumoniae 
strains and antibacterial sensitivity 
assessment in Latvia
Oksana Savicka, R. Zeltmatis, S. Selderina, J. Galajeva, M. 
Donchaka, Jelena Storoženko, Baiba Rozentale – RECUH, 
Latvian Centre of Infectious Diseases, Riga, Latvia
E–mail: oksana.savicka@aslimnica.lv
INTRODUCTION AND AIM. Streptococcus pneumoniae, or 
pneumococcus, is a frequent cause of otitis media, respira-
tory infections and community acquired pneumonia. 
The aim of the study was to determine and compare 
serotypes of S. pneumoniae using Neufeld reaction and 
the capsular sequence typing method (CST) in 2015 
and to determine antibacterial sensitivity in 2011–2015.
MATERIALS AND METHODS. The CST is based on 
a part of the sequence of the wzh gene of the capsular 
locus. In 2015 we performed CST for 17 S. pneumoniae 
strains with already known serotypes and in 2011–2015 
we made 108 antibacterial sensitivity assessments. 
RESULTS. Using the CST method we obtained capsular 
serotypes with the corresponding S. pneumoniae serotype: 
3 capsular serotypes 04-03 (4), 2 07F-01 (7F), 2 09N-01 
(9N), 2 19A-01 (19A), 1: 03-05 (3), 10A-01(10A), 15F-01(15F), 
19F(19F ), 22F-01 (22F ), 23A-01(23A), 35B-01(35B), 
35F-01(35F). Analysis of the data showed that 19 of 108 
S. pneumoniae strains had antimicrobial resistance: 4 
strains (3.7%) to penicillin, all being serotype 14; 15 
strains (13.9%) to sulfamethoxazole/trimethoprim, of 
which 14 were serotype (6 cases), 23F (2 cases) and 6B, 
7F, 9N, 10A, 11, 15B, 19F (one case of each serotype). 
CONCLUSION. The CST and pool antisera performing 
Neufeld reactions showed the same corresponding sero-
type. Development of PCR-based serotyping systems 
has the potential to overcome some of the difficulties 
associated with serological testing. Resistance to peni-
cilin in Latvia is not as high (3.7%) as in other countries 
and belongs to serotype 14 only, However, resistance to 
sulfamethoxazole/trimethoprim accounts for 13.9% of all 
the strains and belongs mostly to serotypes 14 and 23F. 
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W-1. Workshop on the microscopy diagnostics 
of urogenital tract diseases
Alevtina Savicheva, Elena Rybina – The D.O. Ott Research 
Institute of Obstetrics, Gynecology and Reproductology, 
St.Petersburg, Russia
E-mail: savitcheva@mail.ru; elena.rybina@gmail.com
OBJECTIVES. The workshop is conducted with the purpose 
of education, upgrading qualification and maintaining 
professional skills of physicians, contributing to their 
systemic view on the microscopy diagnostics of inf lam-
matory and non-inflammatory diseases of the urogenital 
tract. The target audience of the workshop includes 
dermato-venereologists, obstetricians and gynecologists, 
urologists, infectionists, family physicians and other 
specialists using microscopy at their offices, as well as 
microbiologists and specialists in laboratory diagnostics. 
METHODS. Practical use of microscopy methods for 
the evaluation of the vaginal microbiocenosis, diagnostics 
of bacterial vaginosis, urogenital candidosis, trichomo-
niasis, as well as the assessment of inflammatory reac-
tions of the vaginal and cervical epithelium, enables to 
make a diagnosis already during the patient’s first visit 
and to choose further examinations needed and adequate 
treatment. At the workshop, the theoretical basis of 
light microscopy is discussed, as well as the structure 
of the light microscope, techniques of correct sampling 
for microscopy of wet mount and stained preparations, 
methods of staining preparations, microscopy in trans-
mitted light, evaluation of microscopy data, and inter-
pretation and reporting of microscopy results.
RESULTS. Improvement in theoretical knowledge 
and gaining practical skills in direct microscopy for the 
evaluation of urogenital microflora and diagnostics of 
some sexually transmitted infections, as well as bacterial 
vaginosis, urogenital candidiasis and such inflammatory 
diseases as urethritis, cervicitis. 
CONCLUSIONS. The workshop is an important part 
of the education of physicians who plan to use direct 
microscopy in their practical work. 
W-2. Workshop on method verification
Anders Kallner – Department of Clinical Chemistry, 
Karolinska University Hospital, Stockholm, Sweden
Thinking about method verification in your lab or how 
to establish and monitor quality in the laboratory? This 
workshop will deal with simple statistical principles and 
techniques which are necessary to understand and apply 
in laboratory medicine. There will be a short introduc-
tion to the use of spreadsheet programs on computers. 
After this brief refreshment of metrological basic knowl-
edge and understanding, we will outline the principles 
and methods for estimating and monitoring quality, as 
well as the limitations of the results of measurements, 
with a particular focus on validation of measurement 
procedures. 
Eesti Arst 2016;95(Supplement 1):1–7242
COMMERCIAL PRESENTATIONS
CP-3. New era in point-of-care glucose testing 
in the hospital: regulatory changes and clinical 
significance
Germano Ferrari – NOVA Biomedical Waltham, United 
States of America
E-mail: gferrari@novabio.eu
Point-of-care (POC) glucose meters are daily used in 
hospitals around the world. These meters, often designed 
for consumer use and introduced in hospitals at a later 
stage, pose significant safety risks to patients due to inter-
ferences that can cause meters to over-report glucose, 
resulting in over-dosing of insulin and an increase of 
hypoglycemic events. In 2007 the first glucose meter 
designed for hospitalized patients, which corrected for 
all interferences such as hematocrit, electrochemical 
and non-glucose sugar interferences, was introduced, 
providing a reliable resource to address this unmet 
medical need.
This presentation will focus on:
• Discussing the significance of point-of-care (POC) 
glucose testing for hospitalized patients
• Defining the problems caused by inaccuracy of glucose 
meters
• Presenting clinical cases showing the importance of 
accurate POC glucose testing in hospital
• Discussing the new regulatory requirements for 
bedside glucose measurement systems (BGMS) in 
hospitals
• Presenting clinical evidences supporting the role 
of accurate POC glucose testing in proper glycemic 
management
CP-5. The use of allergen component IgE 
testing 
Péter Csonka – Terveystalo Healthcare Helsinki, Finland
E-mail: peter.csonka@terveystalo.com
Allergens are antigens, usually proteins, which are able 
to bind to specific IgE producing consequently allergic 
reactions. Each living organism is a potential source of 
allergens and each source of allergens contains numerous 
proteins that are called allergen components. Allergen 
components can be grouped into different protein fami-
lies based on their structural similarity. Some allergen 
components are extremely specif ic to the allergen 
source and some are widely cross-reactive between 
different allergen sources. Allergen components differ 
also regarding their stability. Some proteins withstand 
processing reasonably well, but others denature readily, 
for example, by heating. The specificity and stability of 
allergen components are strongly connected to symptom 
probability and severity.
 Molecular allergology, i.e. determination of 
allergen components, provides more precise tools for 
clinical risk assessment. For example, as an allergen 
source, peanuts contain both specific stable allergen 
components and cross-reactive unstable components. 
Persons who are sensitized to specific components are at 
much higher risk for severe allergic reactions compared 
to those who are only sensitized to non-specific cross-
reactive components.
 Symptoms elicited by cross-reacting antibodies 
can lead to unnecessary avoidance of particular food 
products. By distinguishing unspecific sensitization from 
genuine sensitization it is possible to provide patients 
with adequate advice on avoidance and symptom manage-
ment. In cases of cross-reactive sensitization it is advis-
able to identify the primary sensitizer by further testing. 
The exact identification of genuine sensitization to the 
relevant allergen source is also essential when specific 
immunotherapy is considered. Component resolved IgE 
testing will considerably considerably improve diagnostic 
accuracy and patient management.
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CP-6. The next generation in rapid, point of 
care testing 
Johanna Galinski – Quidel Corporation San Diego, 
California, United States of America
Lecture is sponsored by Triolab Oy
E-mail: jgalinski@quidel.com
Sofia, the next generation in diagnostic testing, takes 
rapid diagnostic testing to a new level by integrating 
proven lateral-f low technology, proprietary advanced 
fluorescence chemistry and assay development techniques 
- all of these incorporated into a small bench top analyzer 
that can be used near patient and in laboratory settings.
During this session one can see that Sofia tests are 
easy to use and can be adapted to the needs of any health-
care setting. From the small physician office laboratory 
to larger hospital labs or emergency departments, this 
discussion will highlight the high performance, objec-
tivity, quality control, fail-safe measures, LIS capabili-
ties and expanding test menu in respiratory diseases, 
women’s health, and other areas of testing which make 
Sofia analyzer a perfect solution for the laboratory staff 
and physicians whose aim is to improve their rapid, 
point-of-care testing algorithm.
CP-7. How to improve clinical diagnostics in 
hospital emergency departments
Per Simonsson – Siemens Healthcare AB, Upplands 
Väsby, Sweden
E-mail: per.simonsson@siemens.com
The concept of triage is the most clear-cut difference 
between diagnostics in emergency departments (ED) 
and in other fields of medicine. Decisions are here made 
on small, standardised sets of clinical and biochemical 
parameters and not on extensive investigations. 
Continuous development of panels of appropriate 
tests for specific acute conditions is a fruitful way to 
improve diagnostics. The preanalytical phase of laboratory 
diagnostics must also be high on the agenda. The post-
analytics of IT and interpretation should be discussed.
Turn-around time is important but should not be over-
emphasized. While some condition requires results within 
minutes, the majority do not. However, it is essential that 
the turn-around times are consistent and predictable. 
Improving the quality of an ED is not a single person’s 
job. The key persons of the department must be identi-
fied. The different priorities of nurses and doctors should 
be raised. The laboratory and the ED will then work in 
multidisciplinary groups where lab doctors focus on 
emergency physicians, and lab scientist, on emergency 
nurses. Laboratory leadership should establish good rela-
tions with the leaders in ED. The staff turnover at EDs is 
among the highest in healthcare and presents additional 
challenge when starting collaboration. 
In all discussions, the laboratory staff should be 
prepared to listen to what clinicians really want. And also 
be prepared to accept solutions that are not normally on 
the agenda, or even accepted, at a scientific laboratory. 
The use of venous blood gases, by means of POCT, in 
the triage at EDs is one of several examples that I will 
discuss in my presentation.
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CP-8. Procalcitonin and antibiotic 
management
János Fazakas – Semmelweis University, Budapest 
Hungary
E-mail: jancsidora@gmail.com
The role of PCT in assisting antibiotic therapy has been 
studied extensively, with contradictory results. However, 
to understand the values and limitations of PCT in anti-
biotic management, it is inevitable to understand the 
immunological background of critical illness. The PCT 
distinguishes bacterial infections from SIRS; however, 
individual interpretation of a single elevated PCT could 
sometimes be very difficult. A study of Clech showed 
that medical patients with infection (PAMP) should 
have lower PCT values as compared to surgical patients 
with infection (DAMP+PAMP) in whom PCT elevation 
was found to be 5-10 times higher. The kinetics of PCT 
is always over a single PCT value in case of antibiotic 
commencement. In a recent pilot study we measured 
PCT before initiating antibiotics and further 8 hourly 
(t8, t16, t24) after commencing empirical antibiotic 
therapy, and found a significant difference in the kinetics 
between patients receiving appropriate treatment and 
those receiving inappropriate antibiotic therapy. A PCT 
elevation of ≥55% within the first 16 hours (i.e. from 
t0-t16, AUC 0.78) was associated with reduced hospital 
mortality (35% for the appropriate therapy vs. 65% for 
the inappropriate therapy group). The oversized adap-
tive immune response can induce the immunoparalysis 
condition. According to Rau, patients with secondary 
peritonitis had re-increased PCT levels indicating infec-
tion, but the peak values were found to be significantly 
decreased. This result was confirmed by Charles who 
found that in medical patients PCT was higher during 
primary infection, but it was several times lower during 
a second infectious insult despite the same clinical 
gravity. These data indicate that in the immunopa-
ralysis condition lower levels of PCT should be taken 
just as seriously as high levels in the early course of the 
disease. In a landmark study by Christ-Crain, antibiotic 
exposure was reduced safely by 50% in patients admitted 
to emergency wards with acute respiratory complaints, 
when antibiotic therapy was guided by admission PCT 
levels. Two subsequent multicenter trials also found a 
safe decrease in antibiotic exposure in patients treated 
for infections in ICU. In conclusion, PCT kinetics in a 
multimodal approach helps us to start, continue, or 
change antibiotics and, most importantly, to stop them.
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PP-1. Copy number variation at chromosome 
16p13.11 in Estonian patients
Maarja Andresson1, Olga Žilina1, Kati Kuuse1, Margit 
Nõukas2, Pille Tammur1, Tiia Reimand1, 3, 4 – 1United 
Laboratories, Tartu University Hospital, Tartu, Estonia; 
2Estonian Genome Center, University of Tartu, Tartu, 
Estonia; 3Institute of Biomedicine and Translational 
Medicine, University of Tartu, Tartu, Estonia; 4Institute 
of Clinical Medicine, University of Tartu, Tartu, Estonia
E-mail: pille.tammur@kliinikum.ee
OBJECTIVES. There are many copy number variations 
(CNVs) that are associated with susceptibility for neurode-
velopmental disorders. One such novel CNV is deletion 
and duplication at chromosome 16p13.11 whose clinical 
significance is becoming more firmly ascertained.
The CNVs at 16p13.11 show a broad  range of pheno-
typic manifestations and incomplete penetrance. They 
are significantly enriched in individuals affected by 
developmental delay/intellectual disability, autism, 
epilepsy, dysmorphic features and congenital anomalies. 
Pathogenic 16p13.11 CNVs vary in size, but harbor the 
critical region called interval II (chr16: 15.48-16.32 Mb, 
GRCh37/hg19).
METHODS. We investigated the burden of CNVs at 
16p13.11 (HumanCytoSNP-12 v2-1 BeadChips; Illumina Inc.) 
in a sample of 3,212 individuals with a range of neurode-
velopmental conditions clinically referred for chromo-
somal microarray analysis. The ases were compared 
with 14.747 controls from the Estonian Genome Center. 
We identified 16 patients with CNV within the 16p13.11 
region accounting for ~ 0.5% of the analysed patients 
versus ~ 0.15% of the Estonian general population. Eight 
cases were with deletion and eight were with duplication 
in this region, including one prenatally diagnosed case.
RESULTS. We found that patients with CNV in 16p13.11 
present with varied cl inical features as prev iously 
described. These features are incompletely penetrant. 
All deletions and duplications identified encompass the 
critical region of the CNV. The sizes of the rearrange-
ments vary between 0.3–2.7 Mb.
CONCLUSION. Our findings confirm that genomic 
abnormalities at chromosome 16p13.11 predispose to a 
range of neurocognitive and developmental disorders 
individuals who carry them.
PP-2. Frequency of red blood cell 
alloantibodies among patients at the Hospital 
of Lithuanian University of Health Sciences 
Kauno Klinikos
Asta Balciunaite, Erika Skrodeniene – Department of 
Laboratory Medicine, Lithuanian University of Health 
Sciences, Kaunas, Lithuania
E-mail: a.balciunaite@hotmail.com
OBJECTIVES. Alloantibodies occur as immune response 
to foreign antigens. Identification of alloantibodies to 
red blood cells (RBC) in patients is important as it can 
help prevent blood transfusion complications. Our study 
was carried out in order to determine the frequencies of 
RBC alloantibodies by routine antibody screening and 
their identification in men and women who underwent 
transfusion therapy.
METHODS. RBC alloantibody screening and identi-
fication by gel column agglutination method (BioRad, 
Germany) was carried out from January 2010 to January 
2014 in 2700 patients: 1456 male and 1244 female. The 
mean age of the patients was 48 years (range 18–78 years). 
RESULTS. Screening for alloantibodies to RBC antigens 
was positive in 11.4% (n = 308) patients. Positive results 
were more frequent in women than in men (46.1% and 
53.9%, respectively; p < 0.001). The frequency of alloan-
tibodies to different blood group antigen systems is 
shown in the table.
Table. Frequency of antibodies in relation to blood group 
antigen systems according to patients` gender
Blood 
group 
antigen 
system
Frequency of alloantibodies
2 pGender
Men
n = 1456 n (%)
Women
n = 1244 n (%)
Rh 72 (4.9) 167 (13.4) 59.78 < 0.001
Kell 33 (2.3) 88 (7.1) 36.22 < 0.001
Duﬀ y 8 (0.5) 5 (0.4) 0.31 0.581
Kidd 7 (0.5) 3 (0.2) –* 0.358
Lewis 20 (1.4) 19 (1.5) 0.11 0.739
P 1 (0.1) 1 (0.1) –* 0.999
MNS 7 (0.5) 11 (0.9) 1.65 0.199
Lutheran 36 (2.5) 64 (5.1) 13.43 < 0.001
Xg 2 (0.1) 1 (0.1) –* 0.999
* Fisher exact test was employed for small sample size.
CONCLUSIONS. RBC alloantibodies were more frequent 
in women than in men. The most frequent antibodies were 
against Rh, Kell, Lutheran blood group antigen systems. 
The frequency of Rh, Kell and Lutheran alloantibodies 
in women was higher compared to men.
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PP-3. Gene polymorphısm ınvestıgatıon 
of methylenetetrahydrofolate reductase 
(MTHFR) enzyme in chronıc lymphocytıc 
leukemıa (CLL)
Ramazan Bilgin1, Ahmet Umay1, Emel Gürkan2 – 
1Chemistry Department, University of Cukurova, Balcali, 
Adana-Turkey; 2Haematology Department, University of 
Cukurova, Balcali, Adana-Turkey
E-mail: rbilgin@cu.edu.tr
Methylenetetrahydrofolate reductase (MTHFR) is a 
key enzyme regulating intracellular folate metabolism 
which plays an important role in carcinogenesis through 
DNA methylation. In this study, MTHFR gene A1298C 
(rs1801131) and C677T (rs1801133) polymorphisms were 
determined in a case–control study of 91 patients with 
chronic lymphocytic leukemia (CLL) and 101 healthy 
control subjects using a real-time polymerase chain 
reaction (RT-PCR).
The allele and genotype frequencies of MTHFR gene 
A1298C polymorphism were compared between the 
control and the case groups. In statistical analysis, the 
A allele and the AA genotype were significantly found to 
be a protective variant. There were significant associa-
tions between the control and the case groups in C allele 
and CC genotype of A1298C polymorphism (p = 0.04 and 
p = 0.03). The 1298CC genotype increased 2.58-fold the 
risk of CLL. 
The allele and genotype frequencies of MTHFR gene 
C677T polymorphism were compared between the control 
and the case groups. There was no association between 
the control and the case groups for the allele frequencies 
of C677T polymorphism. However, in statistical analysis, 
677CT and 677CC genotypes significantly increased the 
risk of CLL (p = 0.04, OR = 4.21 (1.10–16.09) and p = 0.05, 
OR = 3.77 (1.00–14.17), respectively).
When the haplotype analysis was performed, there 
were significant differences between the case and control 
groups in terms of haplotype blocks. The AC haplotype 
block (A1298 ve C677) showed a protective effect against 
the risk of CLL (p = 0.034). 
Our results demonstrate that MTHFR gene 1298C 
and C677 alleles have a major effect on the risk of CLL.
PP-4. Biochemistry-based analysis of prenatal 
diagnosis assessing the risk of congenital fetal 
development disorders
Irma Bladžienė, Viltė Marija Gintauskienė – Lithuanian 
University of Health Science, Kaunas, Lithuania
E-mail: irmavainaviciute@gmail.com
INTRODUCTION. Biochemical analysis of serum is an 
important non-invasive test for detecting patients with 
an increased risk of congenital malformations. Modern 
serum analysis helps to identify pregnant women who 
are at risk of neural tube defects, 21 and 18 chromosome 
trisomy (Down and Edwards syndromes).
OBJECTIVE. To evaluate the results of changes in 
biochemical blood markers in prenatal diagnostics.
METHODS. Analysis of 1118 pregnant women‘s (mean 
age 33 ± 5 years), tested at the LUHS medicine labora-
tory in 2014–2015, the results of biochemical blood tests 
intended for prenatal screening. First trimester markers 
(n = 927) (double test): plasma protein A (PAPP-A) and 
free -chorionic gonadotropin (-hCG) analysed in weeks 
11–13 and/or second trimester markers (n = 384) (triple 
test): alpha-fetoprotein (AFP), chorionic gonadotropin 
(hCG), unconjugated estriol (uE3) analysed in pregnancy 
weeks 14–20. Investigations were carried out with the 
Delfin 6000 Xpress analyser using the immunometric 
method, Wallace Oy DELFIA Xpress (Finland) reagent 
kits. Statistical analysis of the data was performed with 
the IBM SPSS 20 program. The patients were divided 
into 4 age groups (under 30, 30–34, 35–37 and over 37 
years.). Differences between the groups were analysed 
by ANOVA statistical method. Data were statistically 
significant at p < 0.05.
RESULTS. In the first trimester pregnant women 
aged up to 30 years were found to have lower -hCG, 
and in the second trimester, higher concentration of 
AFP, compared with the age group of 30–34 years, and 
increased uE3 concentrations compared with all older 
age groups. Higher concentrations of -hCG and lower 
concentrations of uE3 were found in the blood of primi-
gravida aged 30–34 years.
CONCLUSIONS. Pregnant women aged 30–34 years 
showed major biochemical abnormalities, especially in 
the first pregnancy, which indicates the potential risk 
of fetal pathology, and in pregnant women aged up to 
30 years the risk of congenital abnormalities in fetal 
development on the basis of biochemical blood markers 
was the lowest.
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PP-5. MMP-9 as a new marker to predict 
coronary heart disease in native Lithuanians
Andrejus Coj1, Zita Aušrelė Kučinskienė1, Vaidutis 
Kučinskas2 – 1Department of Physiology, Biochemistry, 
Microbiology and Laboratory Medicine, Vilnius 
University, Vilnius, Lithuania; 2Department of Human and 
Medical Genetics, Vilnius University, Vilnius, Lithuania
E-mail: andrejus.coj@santa.lt
OBJECTIVES. Coronary heart disease (CHD) is the leading 
cause of death in the developed world. Traditional 
factors of this disease are known, but there is search for 
new markers, and they are under investigation. Matrix 
metalloproteinase 9 (MMP-9) is one of new potential 
biomarkers. 
METHODS. We have investigated 80 healthy adults 
and 77 with self-reported CHD from different regions of 
Lithuania. They belong to the second generation living in 
the same region of Lithuania; their parents are from the 
same ethno-linguistic region. Diagnosis was confirmed 
on the basis of medical records.
Serum samples were analysed for total cholesterol 
(T-C), LDL cholesterol (LDL-C), HDL cholesterol (HDL-
C), triglycerides (TG), ApoAI, ApoB, hs-CRP, IL-1 beta 
and MMP-9. For statistical analysis we used IBM SPSS 
Statistics 23.
RESULTS. Two groups of individuals were analysed: 
healthy and with CHD. Among 80 healthy adults 39 were 
women and 41 were  men, with a median age of 36 and 
41 years, respectively. In the case of self-reported CHD, 
41 were women (median age 55 years) and 36 were men 
(age 56 years). 
 e T-C, LDL-C, ApoB and MMP-9 were statistically signiﬁ -
cantly lower in healthy individuals (p < 0.0001) compared 
with CHD patients. For healthy persons TG and hs-CRP also 
were lower but the diﬀ erence was not so marked, being 
0.016 and 0.026, respectively.  e HDL-C and ApoA1 did not 
diﬀ er statistically between the groups. 
We found that individuals with MMP-9 ≥ 53 ng/ml 
had 5 times higher risk to develop CHD (OR 5.09; 95% CI 
2.27–11.39; p < 0.001). Furthermore, MMP-9 ROC analysis 
showed a statistically significant value in predicting CHD 
(AUC 0.77; 95% CI 0.69–0.85; p < 0.001). 
Irrespective of age and gender, the IL-1 results were 
below 5 pg/ml, as the reference value recommended by 
the manufacturer. 
CONCLUSIONS. The results of this investigation 
showed that elevated MMP-9 concentration can predict 
CHD and can be considered as a potential biomarker 
for CHD. 
The study was supported by LITGEN Project (VP1-3.1-
ŠMM-07-K-01-013).
PP-6. Serum index: first-year experience at 
Children`s Hospital
Natalija Drapeko1, 2, Audrone Piunoviene1, Audrone 
Eidukaite1, 2 – 1Children’s Hospital, Vilnius University 
Hospital Santariskiu Klinikos, Vilnius, Lithuania; 
2Department of Immunology, State Research Institute 
Centre for Innovative Medicine, Vilnius, Lithuania
E-mail: natalija.drapeko@vuvl.lt
OBJECTIVES. Pediatric patients, irrespective of their 
condition (physiological or pathological, such as dehy-
dration, hypovolemia) are at an exeptionally high risk 
to provide a hemolysed blood sample. This requires 
additional costs and causes discomfort and stress to the 
little patient and his/her relatives. Hemolysed samples 
can be determined by the naked eye and can cause erro-
neous results. However, visual evaluation is subjective. 
The aim of this study was to evaluate the efficiency of 
a serum index program by analysing samples with an 
automated system. 
METHODS. After examining sample hemolysis by the 
naked eye, 146 serum samples that were evaluated as 
hemolysed, were analysed with a Roche Cobas Integra 400 
Plus analyser using the serum index application program. 
RESULTS. A total of 349 hemolysis sensitive biochem-
ical tests were performed for the 146 serum samples. 
The hemolysis index did not exceed the recommended 
individual hemoglobin concentration level for 242 out of 
349 tests, enabling the performance of the biochemical 
tests. This accounted for 69% of all ordered tests.
CONCLUSIONS. Visual determination is not a reliable 
method of sample hemolysis. Automatized systems capable 
of determining the serum index results, based on test 
parameters, should be preferred to visual detection as 
a cheap and a fast way of accelerating and facilitating 
the standard laboratory process.
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PP-7. Serum creatinine determined by the 
Jaffe and enzymatic methods in pediatric 
patients
Natalija Drapeko, Audrone Eidukaite – Children’s 
Hospital, Vilnius University Hospital Santariskiu Klinikos, 
Vilnius, Lithuania; Department of Immunology, State 
Research Institute Centre for Innovative Medicine, 
Vilnius, Lithuania
E-mail: natalija.drapeko@vuvl.lt
OBJECTIVES. The purpose of this study was to compare 
the serum creatinine concentration measured by the 
enzymatic method and by the Jaffe method, and to 
compare the effects of certain interfering substances 
such as glucose and bilirubin on creatinine levels meas-
ured in pediatric patients.
METHODS. Determination of serum creatinine concen-
trations in pediatric patients (with elevated bilirubin or 
glucose, n = 36, and control group, n = 25) was performed 
by the enzymatic method and by the Jaffe method using 
a Cobas Integra 400 Plus Roche analyser.
RESULTS. There was observed high correlation 
between the methods (r = 0.966, p < 0.0001). However, 
the coeff icient of variation (CV %) and bias varied 
between the methods: Jaffe method – CV % 2.8%, bias 
– 7.9%, enzymatic method – CV % – 1.3%, bias – 1.0%. 
We observed significant positive interference due to 
glucose (14–45%) and significant negative interference 
due to bilirubin (28–38%) when the test was performed 
by the Jaffe method. When the test was performed by 
the enzymatic method, no interferences were found.
CONCLUSIONS. In conclusion, the enzymatic method 
is the best choice for determining serum creatinine levels 
in pediatric patients.
PP-8. Plasma corticosteroid analysis using a 
novel reversed-phase solid phase extraction 
sorbent that removes residual phospholipids 
Ignazio Garaguso, Jonathan Danaceau, Kendon Graham, 
Erin Chambers – Waters Corporation, Milford, USA
BACKGROUND. Bioanalysis of drugs and endogenous 
molecules from plasma samples often involves using 
solid phase extraction (SPE) to clean up the matrix and 
concentrate the analytes of interest. Despite the advances 
in SPE sorbents and formats, residual phospholipids 
often remain in extracts and can interfere with analyses 
by causing ion suppression and by prematurely fouling 
analytical columns and MS sources. Using a novel SPE 
sorbent that is designed to remove phospholipids from 
samples, a panel of corticosteroids has been extracted 
from plasma.  This sorbent is also water wettable, enabling 
extraction without the usual requisite preconditioning 
and equilibration steps. This has resulted in a method 
with excellent sensitivity that demonstrates consistent 
recovery, minimal matrix effects, and the elimination 
of > 95% of phospholipids compared to simple protein 
precipitation.
METHODS. 150 μl plasma samples were precipitated 
with 300 μl of a solution of MeOH and ZnSO4. After 
centrifugation, the supernatant was diluted with 4% 
H3PO4 and directly loaded onto a μElution SPE plate. 
All wells were then washed with 25% MeOH and eluted 
with 2 x 25 μl of 90:10 ACN:MeOH. The sample eluates 
were diluted with water and analyzed by UPLC/MS/MS. 
RESULTS. All compounds eluted within 2 minutes. 
Recoveries were consistent, ranging from 72–73% with 
%CVs of less than 5%. Matrix effects were 19% for cortisol 
and less than 10% for androstenedione (Adione) and 
17-hydroxyprogesterone (17-OHP). Calibration curves 
were linear from 0.05–25 ng/ml for Adione and 17-OHP 
and from 1–500 pg/ml for cortisol, with R2 values of 
0.99 or greater. %CV and bias values for quality control 
samples were less than 10% for all analytes at all QC 
concentrations. Comparison with samples that had been 
subjected to protein precipitation only revealed that 97% 
of phospholipids were removed by the SPE procedure.
CONCLUSION. The combination of water wettability 
and phospholipid removal has enabled the development 
of a simple, fast and clean extraction method that results 
in excellent reproducibility, minimal matrix effects and 
the elimination of residual phospholipids.
For Research Use Only, Not for Use in Diagnostic 
Procedures.
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PP-9. HCV genotypes circulating in Latvia in 
2005–2015
Ludmila Guseva, Olegs Vasins, Tatjana Kolupajeva, Lilija 
Lapke, Frida Arsa, Jelena Storozenko, Baiba Rozentale – 
Riga Eastern Clinical University Hospital, Latvian Centre 
of Infectious Diseases, Riga, Latvia
E-mail: ludmila.guseva@aslimnica.lv
BACKGROUND. At present there are more than 40.000 
patients with chronic hepatitis C in Latvia. Genotype 
(GT) and subtype determination of hepatitis C virus 
(HCV) is necessary in order to apply the most appro-
priate therapeutic regimen. At the same time HCV GT 
is predictive of the response to therapy.
AIM. To evaluate the prevalence of different HCV geno-
types circulating in Latvia in 2005–2010 and 2011–2015 
in the general HCV infected population and in patients 
with HIV/HCV coinfection.
MATERIALS AND METHODS. In this study there were 
included the genotyping results of 3209 patients treated 
for VHC in Latvia in 2005–2010 and 3063 patients treated 
in 2011–2015. Another group consisted of patients with 
HIV/HCV coinfection, with 62 and 69 samples, respec-
tively. Genotyping was performed by LinearArray Test, 
Roche and Abbott RT HCV GenotypeII.
RESULTS. In the general population, in 2005–2010 
as well as in 2011–2015, GT1 was predominant, at 64.4% 
and 62.5%, followed by GT3 at 32.3% and 33.8%, GT2 at 
3.3% and 3.2%, GT4 at 1.6 % and 0%, respectively. Differ-
ences were found in the group of HIV/HCV coinfected 
patients. In the first period predominant was GT3 at 
56.5%, followed by GT1at 38.7%, in the later period the 
situation was the opposite (GT1 at 50.7%, GT3 at 47.8%).
In the predominating GT1 subtype 1b was detected 
more often, in 74%, while GT1 subtype 1a was only 
detected in 3.8%. The high proportion of GT1, 21.9 %, 
was not differentiated by subtypes. 
CONCLUSION. The relative prevalence of different 
genotypes in the general chronic VHC population 
remained stable over time (GT1, 64.4% – 62.5%; GT3, 
32.3% – 33.8%). In the predominating GT1 subtype 1b 
was detected more often, which is in accordance with 
previously published data for Latvia. Changes in the 
proportions of GT1 and GT3 in the group of HIV/HCV 
coinfected may be explained by decreasing of IDU in 
the population of HIV infected persons in recent years.
PP-10. Distribution of HLA B27 allele in 
Estonian patients with spondyloarthropathies
Viive Herne, Kaja Mutso, Jaana Juhanson – East-Tallinn 
Central Hospital, Tallinn, Estonia
E-mail: viive.herne@itk.ee
OBJECTIVES. The association between HLA B27 and 
spondyloarthropathies is well known for a long time. 
However, the degree of association between HLA B27 
and spondyloarthropathies varies markedly in different 
forms of spondyloarthropathies and among different 
populations worldwide. To date, no data are available 
about the frequency of HLA B27 in patients with spon-
dyloarthropathies in our country. The aim of this study 
was to determine retrospectively the distribution of the 
HLA B27 allele by different types of spondyloarthropa-
thies in patients attending our clinic.
METHODS. The study included 212 patients admitted 
to the department of rheumatology of East-Tallinn Central 
Hospital who were diagnosed with different spondyloar-
thropathies. The patients were divided into four groups: 
ankylosing spondylitis (AS, n = 58), reactive arthropa-
thies (RA, n = 65), psoriatic spondylitis (Ps, n = 10) and 
undifferentiated inf lammatory spondylopathies (Usp, 
n = 79). Patients with seropositive rheumatoidarthritis 
served as the control group (n = 81). The HLA B27 allele 
was tested using a commercial real-time PCR assay. The 
frequency of the HLA B27 allele was calculated for the 
different groups. 
RESULTS. A significantly higher frequency of the HLA 
B27 allele in patients with spondyloarthropathies was 
found compared with the control group, 45.2% vs. 13.6% 
(p < 0.0001). The highest frequency was observed in AS 
patients, at 86.2%. In the RA group the frequency of the 
HLA B27 allele was 26.2%, in Ps 30% and in 32.9% in Usp.
CONCLUSIONS. Our study confirmed the associa-
tion of HLA B27 with spondyloarthropathies, and the 
importance of HLAB27 testing as an aid to diagnosis of 
spondyloarthropathies, especially in AS. The frequency 
of HLA B27 in our study group of AS was similar to that 
found in some Central and South European countries 
but lower than that reported from Northern European 
countries.
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PP-11. Diagnostics of tick-borne encephalitis 
virus infection from acute antibody negative 
samples by real-time PCR
Anna Ivanova1, Olga Katargina1, 2, Julia Geller1, 
Irina Golovljova1, 3 – 1National Institute for Health 
Development, Tallinn, Estonia; 2University of Uppsala, 
Uppsala, Sweden; 3Tallinn Children’s Hospital, Tallinn, 
Estonia
E-mail: irina.golovljova@tai.ee
Tick-borne encephalitis virus (TBEV) is an RNA flavivirus. 
The infection of humans occurs via bite of an tick while 
the central nervous system (CNS) can be affected. The first 
phase of the disease manifests through flu-like symptoms 
and viraemia occurs simultaneously. No antibodies are 
detectable at this stage. After an afebrile period of 2–10 
days, seroconversion can be observed and detection of 
IgM and IgG by ELISA becomes possible. Thus the main 
problem of the serology based diagnostics, which is widely 
applied at present, is that the infection can be reavealed 
only during the second phase when the symptoms are 
severe and CNS is already involved. Moreover, since the 
viraemic phase is very short and appears simultaneously 
with unspecific symptoms, RNA detection is difficult. 
AIM. To detect RNA of TBEV in early patient serum 
samples. Paired sera of 54 acute TBE patients were 
analysed. The first sera, taken immediately after the 
patient presented at hospital, were screened for TBEV 
specific IgM and all samples were further analysed by 
real-time PCR. For all 54 patients, the infection was 
confirmed by detection of TBEV specific IgM and IgG in 
the second- phase serum, taken approximately 2 weeks 
after the first one.
RESULTS. Out of 33 IgM negative first phase sera, 24 
had detectable levels of TBEV RNA. The presence of RNA 
was also demonstrated in 3 out of 5 samples that were on 
the borderline of IgM negativity and positivity. Finally no 
viral RNA was found in any of the IgM positive samples. 
Out of 27 RNA positive samples 19 were successfully 
amplified and sequenced either in the complete E gene 
or partial E gene region. 
CONCLUSION. IgM negativity might correlate with 
RNA positivity and real-time RT-PCR can be a useful tool 
for early diagnostics of TBE. Real-time PCR analysis of 
samples from patients with a known tick bite history 
or from those who have been to a TBEV endemic area 
could be of benefit.
PP-12. Comparison of hyaladherin expression 
on the surface of T lymphocytes in BAL fluid 
and peripheral blood samples from patients 
with pulmonary sarcoidosis 
Laimute Jurgauskiene1, 3, Radvile Malickaite1, 3, 
Regina Aleksoniene2, 3, Stanislava Simanaviciene1, 3, 
Edvardas Danila2, 3 – 1Heart Surgery Center, Vilnius 
University, Vilnius, Lithuania; 2Vilnius University Clinic 
of Pulmonology and Radiology,Vilnius, Lithuania; 3Vilnius 
University Hospital Santariskiu Clinics, Vilnius, Lithuania
E-mail: laimute.jurgauskiene@santa.lt
OBJECTIVES. It is known that in about 60% of cases the 
course of sarcoidosis is self-limiting with spontaneous 
resolution of the granuloma. Nevertheless, for other 
patients the disease can progress leading to fibrosis with 
organ failure. Some clinical studies show that correlation 
exists between increased levels of hyaladherin (CD44) in 
BAL and various interstitial lung diseases. We hypoth-
esize that alveolar CD44 positive T cells may play a role 
in sarcoidosis pathology, too.  
METHODS. We analysed T cel l subpopulat ions 
(CD4+CD44+ and CD8+CD44+) in BAL and peripheral blood 
(PB) samples of patients (Pts) with lung sarcoidosis and 
in healthy controls (H): 67 Pts (mean age 40 ± 12 years) 
and 12 H (mean age 40 ± 8 years). The BAL and peripheral 
blood samples were analysed by f low cytometry (BD 
FACSCalibur) using three colour monoclonal antibodies 
to cell surface antigens.
RESULTS. Our study revealed significant differences 
in the CD3+CD4+CD44+ cell number between Pts and H 
BAL (75.9 ± 13.5; 47.2 ± 14.6, respectively) and between 
Pts BAL and PB (75.9 ± 13.5; 45.8 ± 9.5, respectively). At 
the same time, the number of BAL CD3+CD8+CD44+ cells 
did not differ significantly between Pts and H (20.7 ± 
12.7; 37.6 ± 14.6, respectively) or between Pts BAL and 
PB (20.7 ± 12.7; 38.6 ± 10.8, respectively).
CONCLUSIONS. According to our investigation, 
CD3+CD4+CD44+ cel ls are play ing a major role in 
sarcoidosis inf lammation; we can conclude that these 
lymphocy tes are implicated in the immunophato-
logical mechanisms of sarcoidosis. Measurement of 
CD3+CD4+CD44+ lymphocytes in BAL can be used in 
determining the activity of sarcoidosis and in predicting 
the disease course.
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PP-13. Implementation of high sensitivity 
architect troponin-I assay in routine practice: 
advantages and challenges
Jolita Jurkeviciene1, Laima Gogeliene1, Armandas 
Karosas1, Dalius Vitkus1, 2 – 1Laboratory of Biochemistry, 
Center of Laboratory Medicine, Vilnius University 
Hospital Santariskiu Clinics, Vilnius, Lithuania; 
2Department of Physiology, Biochemistry, Microbiology 
and Laboratory Medicine, Vilnius University, Vilnius, 
Lithuania
E-mail: jolita.jurkeviciene@santa.lt
OBJECTIVES. The first cardiac-specific Troponin I (cTnI) 
assay was described in 1987 by Cummins et al. Further 
development of TnI assays led to development of high 
sensitivity TnI (hsTnI) assays that lower detection level, 
which allows to evaluate heart attack within two to 
four hours. Abbott recently introduced the hsTnI assay 
for Architect i analysers. The aim of this study was to 
compare the new hsTnI assay with the conventional 
TnI assay.
METHODS. We analysed cTnI concentration in the 
serum samples of 467 unselected patients (183 female 
and 284 male) admitted to the Emergency Department. 
The cTnI concentrations were measured with the Abbott 
Architect i2000 analyser (Abbott Diagnostics, USA) using 
two immunoassays: STAT hsTnI and STAT TnI. Passing-
Bablok regression analysis was used for comparison of 
the methods.
RESULTS. In 45 results out of 467, the ng/l value with 
the conventional TnI assay was 0, while with hsTnI it 
ranged between 0.1–12.9 ng/l with a mean of 2.95 ng/l. 
We determined hsTnI within-run precision using 72 serum 
samples at the 99 percentile level for both males and 
females and average CV = 3.37% was calculated. We found 
poor agreement for the normal and pathological female 
groups: intercept: 1.05 with 95% confidence interval (0.45 
to 1.91), slope: 0.6 (0.45 to 0.8); intercept: -7.33 (-12.78 to 
-1.06), slope: 0.95 (0.91 to 0.98), respectively. The normal 
and pathological male groups demonstrated a similar 
situation: intercept 0.5 with 95% confidence interval 
(0.1 to 1.04), slope: 0.68 (0.62 to 0.76); intercept: -17.66 
(-28.87 to -8.94), slope: 0.9995 (0.95 to 1.03), respectively. 
CONCLUSION. The hsTnI showed higher sensitivity in 
the lower range of cTnI concentration and excellent preci-
sion (CV far below 10%) at the levels of 99th percentiles 
in both the male and female groups. The hsTnI identi-
fies a larger number of patients with myocardial injury 
and requires different approaches in clinical decision 
making. There were found systematic and proportional 
differences between the two methods. 
PP-14. Influx of Syrian refugees and cutaneous 
ceishmaniasis in the city of Adana, Turkey
Ismail Soner Koltas, Mehtap Demirkazık – Department 
of Parasitology, University of Cukurova, Balcalı, Sarıcam, 
Adana, Turkey
E-mail: koltas@cu.edu.tr
OBJECTIVES. More than four million refugees of the 
Syrian civil war have left the country during the course 
of the war. Most of them f led to neighboring Turkey. 
As of December 2015, Turkey was the world’s biggest 
refugee hosting country with close to 2.5 million Syrian 
refugees. Some of them reside in Adana, southern part 
of Turkey. One of four immigrants lives in the southern 
part of Turkey. Cutaneous leishmaniasis represents an 
alarming problem for the whole area of the Middle East. 
Currently, an outbreak has been observed due to the war 
in Syria and the lack of measures to combat the disease, 
particularly in the besieged and medically underserved 
areas. The aim of the study was to draw attention to 
the dramatic increase in the number of new cases of 
cutaneous leishmaniasis in Adana, after the beginning 
of the civil war in Syria.
METHODS. Between January 2014 and January 2016, 
a total of 113 smear samples were taken from cutaneous 
leishmaniasis suspected Syrian refugee cases and sent 
to the Department of Parasitology Laboratory, Faculty of 
Medicine, University of Cukurova, for molecular analysis. 
The samples were analysed with real-time PCR.
RESULTS. Fourty two (37.2%) smear samples were 
positive for cutaneous leishmaniasis according to the 
real-time PCR method. Three different Leishmania species 
were found in the 42 cutaneous leishmaniasis cases by 
real-time PCR: 39.6% Leishmania tropica, 37.1% Leishmania 
infantum and 23.3% Leishmania major. 
The results of real-time PCR were confirmed with 
Leishmania ITS1 DNA sequencing.
CONCLUSIONS. This study revealed that in Adana, 
southern part of Turkey, Syrian refugees are an important 
problem in terms of transmission of cutaneous leishma-
niasis. Refugees in Turkey, and also in Europe, pose a risk, 
given the availability of vectors, for the transmission of 
the disease to new, as yet unaffected countries.
Eesti Arst 2016;95(Supplement 1):1–7252
POSTER PRESENTATIONS
PP-15. Genotyping of hepatitis C viruses for 
selecting the dosage of treatment
Jelena Kopeykiniene1, Raminta Marcinionyte1, Ieva 
Mirskyte1, Jurate Kasnauskiene1, 2 – 1Klaipeda University 
Hospital, Klaipeda, Lithuania, 2Vilnius University, Vilnius, 
Lithuania
E-mail: mirskyte.ieva@gmail.com
OBJECTIVES. Accurate determination of HCV genotype 
is important in the management of patients’ anti-HCV 
treatment. The hepatitis C viral genome is highly vari-
able and is classified into 6 genotype groups, or clades, 
based on phylogenetic analysis of the genomic sequence. 
These genotype groups differ in 31% to 34% of their 
nucleotide sequence positions and in about 30% of their 
amino acid sequence positions. 
We detected HCV RNA and determined the amount 
of viral RNA for 133 primary patients at Klaipeda Univer-
sity Hospital. As a result, 95 out of them were positive 
for HCV RNA and the genotypes of HCV were evaluated.
Samples: human EDTA plasma from 133 patients.
METHODS. Molecular analysis: antiHCV testing was 
performed for ECLIA Elecsys® Anti-HCV II, Cobas, Roche; 
quantitative detection of HCV specific RNA was performed 
using real-time RT-PCR artus HCV RG RT-PCR Kit, Qiagene; 
and HCV genotyping was performed using VERSANT® 
HCV Genotype 2.0 Assay (LiPA), Siemens.
RESULTS. In our analysis 95 out of 133 samples from 
patients were positive for HCV. Genotype 1 was detected 
in 62 samples (1a for 8, 1b for 44, others – unspecified 
subtype of genotype 1), one sample revealed genotype 
2 and genotype 3a was detected in 32 samples. Anti 
HCV testing was performed for 30% of the patients and 
subtenant results were controversial. 
CONCLUSIONS. The most prevalent HCV genotype for 
our HCV patients was genotype 1, 1b subtype. Determina-
tion of the HCV genotype is important when selecting 
an optimal dose of interferon and ribavirin and duration 
of treatment.
PP-16. The role of client-initiated laboratory 
testing in discovering hidden diseases at East-
Tallinn Central Hospital
Liisa Kuhi, Eleonora Ellervee, Marika Tammaru – East 
Tallinn Central Hospital, Tallinn, Estonia
E-mail: liisa.kuhi@itk.ee
BACKGROUND. East Tallinn Central Hospital offers two 
sets of selected analyses, commented by laboratory 
doctors, for persons who are interested in checking their 
health without a doctor’s referral. The set Primary labo-
ratory analyses (PLA) consists of 9 tests (19 parameters) 
and written comments; the set The first step for health 
estimation (SHE) consists of 17 tests (26 parameters) 
and a laboratory doctor’s consultation. 
OBJECTIVE. To describe clients’ characteristics and 
test results’ deviations for the PLA and SHE sets from 
August 2014 to December 2015.
METHODS. Data were retrieved from the hospital’s 
electronic database. The clients’ characteristics, and 19 
parameters (CBC-Diff and urine strip test, Gluc, TSH, 
ALAT, GGT, Crea, eGFR, CRP, Chol) for the PLA set and 
26 parameters (Trigl, HDL-Chol, LDL-Chol, IgE, HCV Ab, 
HBsAg, St-Hb, PSA (male) in addition to the foregoing) 
for the SHE set were described.
RESULTS. The PLA was selected by 108 clients (65% 
female, mean age 44 years; PLA-clients) and SHE was 
selected by 109 clients (57% female, mean age 46 years; 
SHE-clients). Forty-nine SHE-clients had complaints (not 
estimated for PLA).
At least one test result remained outside its reference 
limits (RL) for 90% of the clients. The biggest number of 
result deviations per client was 15/25 parameters for a 
SHE-client. Of all pathologic tests, 38% indicated problems 
of cholesterol metabolism; the results of 59% LDL-Chol, 
52% Chol and 44% HDL-Chol tests remained outside the 
RL. More than of 15% the results were outside the RL 
also for blood glucose, creatinine and IgE. There were 
found no new positive HCV-Ab or HBsAg cases.
Five clients with previously undiagnosed health prob-
lems were referred to specialists. The clients with slight 
deviation in test results were recommended to repeat 
analyses or to visit a family doctor.
CONCLUSIONS. Client-initiated laboratory testing 
accompanied with laboratory doctors’ comments helps to 
discover hidden health problems. Analysis of the results 
allows to improve the selection of tests to be offered.
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PP-17. Mosaic de novo tetrasomy of 5q35 
in a newborn with typical features of 5q35 
duplication syndrome and heart defect
Kati Kuuse1, Pille Tammur1, Piret Ilisson1, Tiiu Ilus1, Mare 
Jürgenson1, Olga Žilina1, 2, Kai Muru1 – 1Department of 
Genetics, United Laboratories, Tartu University Hospital, 
Tartu, Estonia; 2Department of Biotechnology, Institute 
of Molecular and Cell Biology, University of Tartu, Tartu, 
Estonia
E-mail: kati.kuuse@kliinikum.ee
Recently described 5q35 microduplication reciprocal to 
common Sotos syndrome deletion (~2 Mb) is associated 
with microcephaly, short stature, developmental delay 
and delayed bone maturation. The clinical picture is 
largely opposite to that of Sotos syndrome (macrocephaly, 
overgrowth and advanced bone age). The dosage effect 
of NSD1 (5q35) is suggested to be the cause of main 
clinical problems.
We report a dysmorphic newborn with IUGR, micro-
cephaly, short stature, and prenatally diagnosed congen-
ital heart defect (ASD, VSD, left ventricle hypoplasia). 
First routine karyotype analysis (GTG-banding) revealed 
a normal male karyotype. Chromosomal microarray 
analysis (CMA, HumanCytoSNP-12 BeadChip, Illumina 
Inc.) revealed a ~ 8.3 Mb duplication of 5q35.1-qter. To 
localize the extra copy, FISH analysis was made with 
Kreatech hTERT/NSD1 and 5p/5q subtelomeric probes. 
Surprisingly, two additional signals of NSD1 and 5qter 
were seen, located on a small additional marker chromo-
some, which was present in ~ 10% of metaphases (all of 
them were of low band quality and had thus escaped first 
analysis), and in 50% of interphase nuclei. 
Mosaic tetrasomy due to presence of der(5q) marker-
chromosome in ~ 50% of cells results in a typical duplica-
tion picture seen in CMA, as well as in clinical features 
typical of 5q35 duplication. The more severe clinical 
picture compared to common 5q35 duplication can be 
explained by encompassing NK2 (cardiac development) 
and MSX2 (limb and bone development) genes.
PP-18. Comparison of blood sample transport 
via pneumatic tube system and manually by 
courier
Ave Lellep1, Jane Kurm1, Imbi Univer1, Pille Kool2, Karel 
Tomberg1 – 1Laboratory, North Estonia Medical Centre, 
Tallinn, Estonia; 2Department of Pediatrics, University of 
Tartu, Estonia 
E-mail: ave.lellep@regionaalhaigla.ee
OBJECTIVES. It has been recommended that each hospital 
investigates its own pneumatic tube system (PTS) for 
susceptibility to haemolysis. Our aim was to compare 
haemolysis indices (HI), concentration of cellular and 
biochemical components and sample delivery time 
between the Swisslog PTS and courier transport.
METHODS. We verified the Swisslog PTS between 
the blood taking unit and laboratory reception. Dupli-
cate samples were collected for four different sample 
types (EDTA, serum, Na-citrate and Li-heparin, each n = 
20), sent to the laboratory through the PTS (speed 6–8 
m/s) and delivered by a laboratory assistant. Haemolysis 
indices were measured spectrophotometrically (Cobas 
6000, Roche Diagnostics). Selected tests were analysed 
(white blood cells, platelets, INR, potassium). Differences 
between the pairs of samples were evaluated with a 
paired t test or a sign test (in case distribution was not 
normal). A p-value of ≤ 0.05 was considered significant. 
RESULTS. There was no significant difference in the 
HI, leucocyte, platelet or INR values between the samples 
sent via the PTS or those delivered manually (p > 0.05). 
Mean potassium values with the 95% confidence interval 
were 4.29 (4.11–4.46) for the PTS and 4.20 (4.02–4.37) 
mmol/l for courier transport (p = 0.0078). However, there 
was no significant difference in HI for these potassium 
samples. The geometric mean delivery time of the samples 
was 23 (20–27) min by the courier and 17 (14–20) min 
via the PTS (p = 0.0045, n = 80).
CONCLUSION. Transport of blood samples via the PTS 
is faster and does not influence results to a higher degree 
than routine transport by the courier. Higher potas-
sium values cannot be explained by possible haemolysis 
induced by PTS.
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PP-19. Prevalence of non-tuberculous 
mycobacterium strains isolated from clinical 
specimens at North Estonia Medical Centre 
2001-2015
Klavdia Levina – Laboratory, North Estonia Medical 
Centre, Tallinn, Estonia
E-mail: klavdia.levina@regionaalhaigla.ee
Mycobacteria are widespread microbes in the nature. 
At present more than 120 different species of myco-
bacteria are known. Mycobacteria that are causative 
agents of human and animal tuberculosis are called the 
Mycobacterium tuberculosis complex (MTBC). Some of 
mycobacteria that are not MTBC have been considered 
to be named non-tuberculous mycobacteria (NTM). The 
diseases caused by NTB are called mycobacteriosis. 
OBJECTIVES. The incidence of tuberculosis in Estonia 
shows a trend of decrease. The aim of the study was to 
analyse the prevalence of NTM strains on the basis of 
clinical specimens.
METHODS. The NTM species were isolated from clin-
ical material that had been sent to the mycobacteriology 
laboratory for diagnostic purposes during 2001–2015. 
The pathological material was decontaminated by 
NaOH+NALC and cultivated on Löwenstein-Jensen and 
Middlebrook. The NTM was identified by the GenoType 
Mycobacterium CM/AS test (Hain Lifescience GmbH).
RESULTS. In 2001–2015, of 106,820 investigated speci-
mens, 12,881 (12%) MTBC and 880 (0.82%) NTM strains 
were identified. 
The leading NTM species isolated were M. avium (48%), 
M. gordonae (12%), M. fortuitum (10%) and M.intracellulare 
(5%). Among rarely isolated NTM there were M.kansasii, 
M.xenopy, M.szulgai and M.abscessus. Of the NTM, 72% 
were cultivated from sputum, 5% from blood and 23% 
from other materials. 
The number of patients infected with NTM was 85 
in 2001–2005, 210 in 2006-2010 and 237 in 2011–2015. 
Of the patients releasing NTM, 35% were older than 65 
and 9% were younger than 30 years of age. A combination 
of TBC and HIV was found in 317 (8.3%) and a combina-
tion of NTM and HIV was found in 56 (10.5%) patients. 
CONCLUSIONS. During the last 15 years the prevalence 
of NTM in patients’ material has increased approximately 
three times. The most prevalent species is M. avium. 
PP-20. Peculiarities of lipid metabolism 
parameters for cardiovascular disease risk 
assessment
Eglė Milkintaitė, Viltė Marija Gintauskienė – Hospital 
of Lithuanian University of Health Sciences Kaunas 
Clinics, Lithuanian University of Health Sciences, Kaunas, 
Lithuania
E-mail: egle.milk@gmail.com
INTRODUCTION. In diagnostics of cardiovascular disease 
it is necessary to pay attention to age, gender, concentra-
tions of total cholesterol (TChol), high density lipopro-
tein (HDL), low density lipoprotein (LDL) choltesterols, 
triglicerides (Tg) and other risk factors. A significant 
diagnostic value in assessing the condition of the patient 
can be ascribed to lipid relative values: TChol/HDL, LDL/
HDL and Tg/DTL.
MATERIALS AND METHODS. Analysis of the test 
results of 876 patients (443 male and 433 female) with 
an average age 59.5 ± 15.6, with cardiovascular, chronic 
liver, renal and hormonal imbalance diseases, who were 
treated at the Hospital of Lithuanian University of Health 
Sciences Kaunas Clinics. The patients were divided into 
3 age groups (up to 50, 50−65 and over 65 years). The 
lipid profile parameters (TChol, HDL, LDL cholesterols 
and Tg), blood analysis, relative values (TChol/HDL, 
LDL/HDL, Tg/HDL) and atherogenic factor (AF) were 
calculated. Statistical analysis was performed using 
the IBM SPSS 20.0 statistical data analysis package. The 
result was statistically significant when the probability 
of error was p < 0.05.
RESULTS. Women aged 50−65 years with chronic liver, 
renal and hormonal imbalance diseases were found to 
have the lowest lipid profile parameters, while men with 
cardiovascular diseases were found to have the highest 
values of AF and lipid ratios (p < 0.05). Lipid metabolism 
parameters for older patients than 65 years were found 
to be better compared with those for patients younger 
than 50 years, especially in the group of men with cardio-
vascular disease (p < 0.05).
CONCLUSIONS. Women aged 50−60 years with a 
chronic disease can be assigned an increased risk of 
developing cardiovascular disease.
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PP-21. Screening for EGFR, RAS and BRAF 
genes mutation in NSCLC, MCRC and melanoma 
specimens
Ieva Mirskyte1, Jurate Kasnauskiene1, 2, Alvydas Casas1 
– 1Klaipeda University Hospital, Klaipeda, Lithuania; 
2Vilnius University, Vilnius, Lithuania
E-mail: Mirskyte.Ieva@gmail.com
OBJECTIVES. The rapid development of targeted therapies 
has tremendously changed the clinical management of 
setting the stage for a number of tumour types. Evidence 
has accumulated that targetable drugs show the best 
efficacy and improve progression of survival rates. For 
cancer patients whose tumours have a specific genotype, 
molecular testing for predictors of therapy response has 
become the standard of care. At present, for selecting 
appropriate target therapy, testing for EGFR mutations 
in lung adenocarcinoma, RAS mutations in mCRC, and 
BRAF mutations in melanoma is carried out in oncology 
practice. 
We performed predictive testing for the mutation 
status of EGFR, RAS and BRAF genes for patients with 
metastatic lung, CTC and melanoma patients from FFPI 
material at Klaipeda University Hospital, Lithuania. 
METHODS. Samples: formalin-fixed tumour samples 
were obtained from and diagnosed for 152 patients at 
Klaipeda University Hospital, Lithuania.
Molecular analysis: mutation test for qualitative 
detection and identification of mutations therascreen 
EGFR Pyro Kit in exons 18, 19, 20 and 21 of the EGFR 
gene, therascreen KRAS, NRAS Pyro Kit (hot-spot) and 
therascreen BRAF Pyro Kit V600 codon in DNA derived 
from formalin-fixed paraffin-embedded (FFPE) human 
tumour tissue. 
RESULTS. Altogether 71 DNA samples from NSCLC 
patients were tested for EGFR mutations and 13 cases 
(18.3%) out of 71 were EGFR mutated. 
Sixty DNA samples from mCRC patients were tested 
for RAS mutations, 33 cases (55%) were RAS mutated. 
Twenty-one DNA samples from 21 mCRC patients 
were tested for BRAF mutations, 11 cases (52%) were 
BRAF mutated. 
CONCLUSIONS. An up to date concept of personalized 
therapy for NSCLC, CTC and melanoma involves charac-
terization of individual patient’s tumour mutation status.
Rapid molecular results are essential for diagnosis of 
advanced malignant tumour because of the urgent need 
to initiate the most appropriate therapy for a certain 
disease type.
PP-22. The effect of physical training 
on platelet aggregation and fibrinogen 
concentration in patients with chronic heart 
failure
Aušra Mongirdienė1, 2, Raimondas Kubilius3 – 1Institute 
of Cardiology, Lithuanian University of Health Sciences, 
Kaunas, Lithuania; 2Chair of Biochemistry, Lithuanian 
University of Health Sciences, Kaunas, Lithuania; 
3Cardiology Clinic, Lithuanian University of Health 
Sciences, Kaunas, Lithuania
E-mail: ausra.mongirdiene@mail.com
OBJECTIVES. Data about the importance of physical load 
on hemostasis in patients with chronic heart failure 
(CHF) are controversial. The aim of the study was to find 
out the effects of long-term physical load on fibrinogen 
concentration and platelet aggregation. 
METHODS. Platelet aggregation and f ibrinogen 
concentration were investigated in 144 patients. The 
trained subjects and the controls were investigated as 
follows: on admission to hospital, after treatment at 
hospital, after 6 months, after 1 year. The indices were 
investigated before and after physical load. 
R ESULTS. Fibr inogen concentrat ion increased 
significantly after the application of physical load in all 
investigated stages for both groups (p < 0.045). In the 
course of treatment, fibrinogen concentration gradually 
decreased in the trained subjects (p < 0.02) in all investi-
gated stages. Platelet aggregation investigated with ADP 
increased significantly after physical load in all stages for 
both groups (p < 0.001 and p < 0.045, respectively) and 
decreased during the different stages of investigation 
for the groups of the untrained (p < 0.02) and trained 
subjects. Platelet aggregation investigated with ADR 
decreased consistently before applying physical load 
during the different stages of investigation for the groups 
of the trained subjects and untrained patients (p < 0.02). 
CONCLUSIONS. Physical training reduces fibrinogen 
concentration in patients with CHF. It remains unclear 
whether physical training can have an effect on decrease 
in platelet aggregation in patients who have been engaged 
in long-term physical training. 
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PP-23. Results of the effect of hypochlorous 
acid on platelet aggregation in healthy 
subjects and in patients with heart failure in 
vitro
 Aušra Mongirdienė1, 2, Vilius Skipskis1, Jolanta 
Laukaitienė2, 3 – 1Institute of Cardiology, Lithuanian 
University of Health Sciences, Kaunas, Lithuania; 
2Chair of Biochemistry, Lithuanian University of 
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OBJECTIVES. It is important to explore the impact of 
oxidants on platelet aggregation as this might serve 
as a niche for treatment. The aim of this study was to 
determine the dependence of the effects of hypoclorous 
acid on the intensity of platelet aggregation in vitro in 
healthy subjects and on HOCL concentration in heart 
failure patients.
METHODS. Were investigated: healthy subjects (n = 10) 
and heart failure patients (n = 18). Platelet aggregation 
was determined with an optical 2-channeled Chrono-log 
platelet aggregometer. Aggregation was initiated with 
ADP (3.8 mmol/l) solution. We used 6 samples from the 
same person` s plasma. To each sample 10 μl HOCl of 
different concentrations were added: 2.12 mm/l, 7.06 
mm/l, 10.59 mm/l, 21.18 mm/l, and 43.4 mm/l being final 
concentration. To the control sample the same volume 
of physiological solution was added. The samples were 
incubated for 30 min at 37 0C, and the intensity of platelet 
aggregation using ADP was determined (%).
RESULTS. It was found that high concentrations of 
HOCl (2.12 to 43.4 mm/l) significantly decreased platelet 
aggregation in both groups. The increasing concentration 
of HOCl was reversely proportional to the intensity of 
platelet aggregation. The decrease of platelet aggregation 
intensity in the plasma of patients affected with HOCl 
in vitro was more pronounced compared with healthy 
subjects (42.6% and 36.1%, respectively).
CONCLUSIONS. The intensity of platelet aggregation 
significantly decreased depending on HOCl concentra-
tion in plasma in vitro. Heart failure patients were more 
affected than healthy subjects.
PP-24. Prevalence of single nucleotide 
polymorphisms RS12979860 and RS8099917 
of the interleukin 28B gene among hepatitis C 
virus positive patients at East-Tallinn Central 
Hospital
Kaja Mutso, Viive Herne – Central Laboratory, East-
Tallinn Central Hospital, Tallinn, Estonia
E-mail: kaja.mutso@itk.ee
OBJECTIVES. The natural course of hepatitis C virus 
(HCV) and response to therapy depends on viral factors 
and host factors (age, sex, liver fibrosis etc). Additionally, 
there is a new host component – two single nucleotide 
polymorphisms (SNPs) near the interleukin 28B (IL28B) 
gene. The SNP rs12979860 genotype CC and the rs8099917 
genotype TT are associated with increased spontaneous 
clearance of the HCV genotype 1 and are also predictors 
of sustained virologic response (SVR) following pegylated 
interferon- and ribavirin (PEG-IFN/RBV) therapy. The 
aim of the present study was to estimate retrospectively 
the genotype frequency of IL28B SNPs in HCV-infected 
patients at East-Tallinn Central Hospital.
METHODS. Genomic DNA was isolated from whole 
blood samples collected from 98 HCV infected patients. 
Detection of polymorphisms rs12979860 and rs8099917 
was performed with commercial real-time PCR kits using 
a Rotor Gene Q thermal cycler.  
RESULTS. Frequencies of the IL28B 2 SNP genotypes 
were determined in 98 HCV-infected patients. The 
favourite genotype CC/TT (rs12979860/rs8099917) was 
detected in 19.4% of the cases, the unfavourite geno-
types CT/TG and TT/GG, in 44.9% and 3.1% of the cases, 
respectively.  
Predominantly, there were carriers of the rs12979860 
CT genotype (64/98, 65%). The frequency of the favourite 
rs12979860 C-allele was 52%. 
CONCLUSIONS. The results indicate that IL28B SNP 
genotyping may be an effective tool for physicians with 
patient management predicting the likelihood of HCV 
response to therapy. The selection of our study group 
explains lower rs12979860 C-allele frequency compared 
with overall population frequencies. 
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myeloperoxidase in pediatric patients during 
chemotherapy
Sergey Nikulshin, Santa Kursite, Zhanna Kovalova, Iveta 
Tolstikova, Dagne Gravele – Children’s Clinical University 
Hospital, Riga, Latvia
E-mail: nikulshin@gmail.com
Leukopenia is l ife-threatening in pediatric patients 
undergoing chemotherapy; still, there are few criteria 
for predicting its severity and outcome. Neutrophil 
myeloperoxidase (MPO) is produced in azurophilic gran-
ules from the earliest stages through maturation and is 
excreted in activation and phagocytosis. The analyser 
Advia 2120i measures MPO to separate myeloid cells as 
Myeloperoxidase Index (MPXi, range -10–+10).
OBJECTIVES. The aim was to analyse episodes of chem-
otherapy-induced leukopenia in children for dynamics of 
leucocyte count (WBC) and MPXi. The data for 2011–2013 
from the Children’s Clinical University Hospital LIS were 
selected. Altogether 336 episodes of leukopenia were 
found; 294 representative cycles of 85 patients with a 
total of 3824 blood tests were studied. The MS Excel and 
IBM SPSS v.21 were used for statistical analysis.
RESULTS. In 283 cycles (96%) there was a synchro-
nous drop in WBC and an increase of MPXi above +10, 
followed by synchronous normalization. In 5 cycles (2%) 
MPXi did not reach +10. Irregular MPXi f luctuations 
were seen in 6 cycles (2%). WBC and MPXi reached their 
peaks simultaneously (median difference 0 days), MPXi 
reverted to normal earlier (median 1 day, the difference 
significant, p << 0.0001).
Negative correlations between MPXi and WBC and 
neutropenia grade were found (p << 0.0001 for both). 
Duration of leukopenia correlated with time span of MPXi 
being > +10, with increase in MPXi from initial through 
peak and with maximal attained MPXi (p < 0.001 for all).
CONCLUSIONS. The results strongly support the 
relat ionship between destruction and rest itution 
of neutrophils during chemotherapy and their MPO 
content. In 98% leukopenia cycles, cellular MPO increased 
synchronously with a decrease in WBC and decreased 
along WBC recovery. Thus, cellular MPO could be used 
as a predictive factor in induced leukopenia. The MPXi 
by Advia 2120i is excellent for monitoring since it can 
be measured during routine blood tests. 
The results of the study are completely original, there 
are no available comparable published data.
PP-26. Red cell indices and C-reactive protein 
in pediatric patients are closely related
Sergey Nikulshin, Dagne Gravele – Children’s Clinical 
University Hospital, Clinical Laboratory, Riga, Latvia
E-mail: nikulshin@gmail.com
Disease-related anemia in children, though a common 
knowledge, is poorly described; only sporadic historical 
data, studies on small hospital cohorts or in general 
population are available in the literature.
OBJECTIVES. The aim was to correlate blood red cell 
indices (HGB, RBC, MCV, MCHC) with CRP in pediatric 
patients in order to analyse relations between anemia 
and inflammation.
METHODS. 70024 routine blood tests (Advia 2120i) 
with parallel CRP (Cobas 60000) performed at Riga 
Children’s Clinical University Hospital in 2011–2013 were 
analysed. Results from the Emergency, Neonatology, 
Intensive Care, Hematooncology, Infections and Outpa-
tient departments were further studied. Statistics was 
performed by MS Excel and IBM SPSS v21 (Spearman rho 
for correlations and Mann-Whitney U for differences).
RESULTS. Of the samples 27.8% were anemic after 
age and gender adjustment, 11.7% of them were possibly 
iron-deficient (MCHC low, MCV low/normal); only 0.3% 
had both high MCV and MCHC. The HGB, RBC and MCV 
significantly correlated with CRP for the total cohort (p 
<< 0.0001). The HGB was significantly lower in patients 
with CRP 5-50 than in patients with normal CRP for 
all groups but Neonatology; and significantly lower in 
patients with CRP > 50 than in patients with CRP 5-50 
for all groups. The CRP was significantly elevated in 
patients with anemia (p << 0.0001 for the total cohort 
and for all groups). 
The RBC count was elevated in 3.5% of the tests after 
age and gender adjustment. Paradoxically, it was associ-
ated with a significantly lower CRP for the total cohort, 
and for Emergency, Intensive Care and Infections.
CONCLUSIONS. The study was performed on a much 
broader basis compare with previous reports. The results 
support observations of frequent anemia in a pediatric 
hospital setting, mostly not iron-deficient. The HGB 
and CRP were highly significantly related for the whole 
cohort and for the specific patient profiles. No studies of 
occasionally found erythrocytosis have been published; 
the finding of plethora associating with lower CRP needs 
further analysis.
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C-reactive protein testing methods
Solvita Pūga1, Lada Korpeikina1, Ludmila Eņģele1, Natalja 
Reuta1, Oļegs Šuba1 – 1Riga East University Hospital, Riga, 
Latvia
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INTRODUCTION. A diﬀ erential diagnosis of infection caused 
by either bacteria or other microbial organisms is essential 
for eﬀ ective treatment and prognostic assessment. Current 
clinical laboratory methods in the diagnosis of bacterial 
infections (incl. sepsis) are either non-speciﬁ c or require 
longer turnaround times. Procalcitonin (PCT) and C-reactive 
protein (CRP) are biomarkers of bacterial infection with 
distinct clinical qualities, and they can be used in parallel 
to improve the speciﬁ city and sensitivity of the diagnosis 
of bacterial infection / sepsis.
 ere is currently no agreement-based reference method 
for PCT and CRP testing, but all laboratory methods for 
quantiﬁ cation of PCT and CRP are based on immunoassays.
AIM. To compare the PCT and CRP results measured 
with the Roche Cobas and hybcell automated assays.
MATERIAL AND METHODS. 12 clinical samples from a 
Sepsis clinic were tested with two diﬀ erent PCT and CRP 
testing methods – hybcell Inﬂ ammation Blood xA (hybcell 
technology based on cylindrical microarrays) and PCT 
BRAHMS and CRP-Latex immunoturbidimetric automated 
assays (Roche). Devices used: hyborg Dx Red (Cube Dx 
GmbH, Roche Cobas Integra 400plus, Roche Cobas e411.
 e study was launched on 01.01.2016. Clinical samples 
were selected to cover clinically signiﬁ cant areas: PCT nega-
tive and elevated, PCT that predicts sepsis, CRP within the 
reference range and elevated.
Deming regression analysis and R2 were used to compare 
the results.
PRELIMINARY RESULTS. Absolute values of hybcell CRP 
results correlated with those obtained with Roche Cobas, 
with R2 = 0.6423.  is correlation is acceptable.
 e absolute values of hybcell PCT results correlated 
with those obtained with Roche Cobas, with R2 = 0.98.  is 
correlation is very good, however, there was noted a shift 
in absolute values around factor 5.
CONCLUSIONS. In general, there is good correlation of 
hybcell and Roche Cobas values for both parameters.
 e reason for a shift in absolute PCT values can be 
explained with the use of diﬀ erent antibodies which bind 
to diﬀ erent parts of the PCT molecule: in the case of PCT 
BRAHMS it detects the intact CT/CCP protein, but hybcell 
detects N-PCT/CT. If PCT molecule in patient` s serum is 
present undigested, there can be expected similar results 
with both systems.
Further evaluation of both testing methods should be 
performed to evaluate clinical outcome as well as to give 
recommendations to clinicians for interpretation of results.
PP-28. Research of enterobiaisis among 
nursery school children in four Estonian 
counties
Mare Remm, Helin Sinimets, Pirgit Rattasepp, Maia 
Kukner, Merlin Matvere, Getter Annuk – Tartu Health 
Care College, Tartu, Estonia
E-mail: mareremm@nooruse.ee
INTRODUCTION. Since 2002 the Tartu Health Care 
College has researched enterobiasis in Estonian nurseries. 
As approximately ten years have passed since the first 
studies, there is reason to find out if infection rate among 
children has decreased. The aim of the research was to 
find out the distribution of pinworms and conditions 
inf luencing the distribution in four Estonian counties.
METHODS. The research was conducted in Jõgeva, 
Tartu, Viljandi and Rapla counties. During 2012–2015, 
altogether 1322 children were examined in 38 nurseries. 
For examination, the traditional anal swab method was 
used. Questionnaires were collected only from the parents 
whose children provided anal swabs; altogether 1102 
completed questionnaires were returned. The question-
naires included questions about home environment and 
parent’s awareness of pinworms. Interviews with teachers 
included questions about conditions at the nursery. 
RESULTS. Altogether 259 (19.6%) children were 
infected with pinworms on the basis of the single examina-
tion, infection rate varied by counties. Infection rate was 
slightly higher among boys, at 21.6%, compared to girls, 
at 17.2% (p < 0.05). Infection rate depended on child’s 
age (p < 0.05). Children’s infection is related to their 
mothers’ level of education. The highest infection rate 
occurred among children whose mothers had primary 
education (rate 27.9%) and the lowest rate occurred 
among the children whose mothers had higher educa-
tion (11.8%, p < 0.05). 
CONCLUSION. Compared to the research conducted 
in several Estonian counties in 2002–2007 the infection 
rate has not markedly decreased. Even though there 
is relationship between mothers’ level of education 
and children’s rate of infection, it seems that the level 
of education is not connected with the awareness of 
enterobiasis. Further research is needed concerning 
the relationship between fathers’ level of education 
and infection rate and awareness of enterobiasis among 
nursery school teachers.
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patients with positive anti-neutrophil 
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OBJECTIVE. Autoantibodies against neutrophil cyto-
plasmic antigens (ANCA), which react with the proteolytic 
neutrophil granule enzymes, proteinase-3 (PR3) and 
myeloperoxidase (MPO), have been found in patients 
suffering from various forms of autoimmune vasculitis. 
The aim of this research was to identify and evaluate 
specific PR3 and MPO antibody rate among ANCA posi-
tive patients depending on gender and age.
METHODOLOGY. Altogether 78 ANCA positive patients 
were analysed. Additionally, the ANCA cases were studied 
by selecting a qualitative indirect immunofluorescence 
method using EUROPLUS Granulocy te Mosaic 25, 
Germany. By assessing the fluorescence type of antibody 
in formalin and methanol and reactions with PR-3 and 
MPO antigens, ANCA was divided into cANCA, typical 
and atypical pANCA. Statistical analysis of the data was 
performed using the IBM SPSS 20 program.
RESULTS. Twenty-nine (37.2%) of 78 ANCA positive 
patients were found to be typical pANCA positive, 11 
(14.1%) were found to be atypical pANCA, 14 (17.9%), 
cANCA and 24 (30.8%), ANCA negative. The specific anti-
bodies against PR3 were found in all 14 subjects with a 
cANCA positive; specific antibodies against MPO were 
found in 17 (58.6%) of 29 patients with typical pANCA 
positive. In 54 women participating in this research the 
most frequent were typical pANCA (41%), less frequent 
were atypical pANCA (15%) and cANCA (13%). For 24 
tested men the frequency of pANCA and cANCA was 
distributed equally, i.e. by 29%. Assessing the results by 
age, the atypical pANCA were more often found in older 
women than in men (73.3 ± 8.8 and 49 ± 21.9, respec-
tively), while cANCA was found in both younger women 
and younger men (61 ± 13.8 and 45.6 ± 12.9, respectively).
CONCLUSIONS. Typical pANCA are more commonly 
found in women, while pANCA and cANCA are equally 
found in men, and atypical pANCA are found in older 
women and younger men. For the interpretation of ANCA 
results, additional investigations of antibodies against 
MPO and PR3 antigens would provide complementary 
diagnostic information and help to diagnose, predict 
and monitor the progress of vasculitis more accurately.
PP-30. Acquired cytogenetic finding in a 
patient with acute myeloid leukemia
Inguna Stalidzane, Silvija Ozolina, Didzis Gavars – 
E. Gulbis Laboratory, Riga, Latvia
E-mail: inguna@egl.lv
Acute myeloid leukemia (AML) is a disease resulting from 
the clonal expansion of myeloid blasts in the peripheral 
blood, bone marrow or other tissues. Clinically, morpho-
logically and genetically it is a heterogeneous disease 
and may involve only one or all myeloid lineages. 
Cytogenetic analysis is an integral part of the diag-
nosis and management of patients with AML to identify 
a series of recurrent genetic markers by which AML is 
subcategorised.
The aim of the study was to analyse the results of 
cytogenetic examination carried out among 123 patients 
of different Caucasian populations with AML during 
2006–2015 at the E. Gulbis laboratory in Latvia.
Cytogenetic analysis was performed from cultured 
cells of bone marrow or peripheral blood without stimu-
lation, using the GTG banding method, and was karyo-
typed according to the International System for Human 
Cytogenetic Nomenclature (ISCN). The FISH method was 
used in the case of need to determine cryptical changes 
or to confirm discovered ones. 
Chromosome analysis in a patient with AML helped to 
detect structural and numerical abnormalities in 61 (49%) 
samples. The group of the most significant changes was 
t(8;21) or its variations (7%); changes of 7.chromosome 
were found in 6% of the samples; t(15;17) were found in 
6%; 5.chromosome changes, in 5%, including complex 
changes; 8.chromosome  trisomy was discovered in 4% of 
the cases (as the sole change); inv(3) and its variations, in 
3%; inv(16), in 3%, deletion (9), in3% and 11q23 changes 
were found in 3% of the samples; t(6;9), in 1%.
In this study we obtained data that are similar with 
literature data on well established occurrence of genetic 
AML pathology. However, to determine new diagnostically 
important aberrations, especially in case of a normal 
karyotype, use of molecular methods would be required.
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OBJECTIVES. The aim of the study was to compare 
FNAB cytological and histopathological results after 
thyroidectomy.
METHODS. All patients were subjected to FNAB at 
one institution from January 2015 to December 2015. A 
total of 1203 specimens were tested (1072 female and 
131 male, avarage age 55.8 years). Cytological specimens 
were stained by Romanowsky-Giemsa-Leischman modifi-
cation. All cytological results were grouped according to 
the BSRTC system. Using the Riga East Clinical Hospital 
information program, we obtained data of 62 histological 
evaluations for operated patients with cytological find-
ings: atopia of undetermined significance (AUS), follicular 
neoplasm or suspicion for a follicular neoplasm (FN/
SFN), suspicion for malignancy (SFM) and malignancy.
RESULTS. Among the 1203 specimens of FNABs, 11.6% 
(140) were reported as non diagnostic, 79.7% (959) as 
benign, 0.6% (7) as AUS, 1.2% (14) as FN/SFN, 3.2% (39) 
as SFM and 3.7% (44) as malignant. Among 62 histo-
logical evaluations, 22.6% (14) were reporded as benign, 
61.3% (38) as papillary carcinoma, 8.1% (5) as medullary 
carcinoma, 4.8% (3) as folliculary carcinoma, 1.6% (1) as 
anaplastic carcinoma and 1.6% (1) as papillary carcinoma 
for 1 thyroid lobe and medullary carcinoma for the other. 
In our study, 39 cases where FNAB results were evalu-
ated as suspicious for malignancy, 18 were operated on, 
and 10 were determined as malignant. Also, 44 patients 
in malignant cytological category, 37 were operated on, 
and 32 were determined as malignant. Among 5 patients 
whose FNABs were indicated as follicular neoplasms 
and in whom histological evaluation was performed, 
surgical pathology findings of 4 cases were reported as 
malignant. There were no histological data for 9 cases 
in FN/SFN category.
CONCLUSIONS. We consider that the patients reported 
as having follicular neoplasms should be operated on. In 
summary, our study demonstrated that thyroid FNAB, 
stained by Romanowsky-Giemsa-Leischman modification, 
is an accurate and relatively precise tool for diagnosis of 
thyroid malignancy.
PP-32. Latvian experience in surveillance of 
polio and other enteroviruses circulation
Natalija Zamjatina, Larisa Firstova, Larisa 
Metlova,Galina Rjazanceva, Edite Bleidele, Tatjana 
Kolupajeva, Jelena Storozenko,Baiba Rozentale – Riga 
East University Hospital, Latvian Infectology Centre, 
Riga, Latvia 
E-mail: tatjana kolupajeva@aslimnica.lv
OBJECTIVES. Laboratory survei l lance focusing on 
revealing enteroviruses in clinical material, especially 
from patients with acute f laccid paralysis, as well as on 
virus findings in environmental samples serves as the 
background for completing the WHO programme and the 
main control procedure for polio circulation in Latvia.
Detection of the spectrum of circulated non-poliovi-
ruses enteroviruses for diagnosis conformation and for 
surveillance procedures plays the indicator role in the 
control of polio virus in Latvia.
METHODS. Clinical materials as faeces, CSF, pharyn-
geal swabs, post mortem collected specimens and sewage, 
were analysed according to the WHO recommendation. 
Three different cell lines: L-20B, Hep-2C, RD(A) were used 
for enterovirus isolation. Isolated polio and enterovirus 
strains were characterized for serotype on the basis of 
neutralization reaction with specific antisera. Entero 
RNS detection in samples was completed using the 
conventional PCR method.
RESULTS. The last wild polio virus in Latvia was 
detected in 1965. It was WPV1 isolated from sewage. 
Since that year only polio vaccine associated viruses 
have been detected in Latvia. Polioviruses were found in 
98 samples of sewage water (Sabin PV1- 38, PV2-29, and 
PV3-31) and 8 samples of faeces (Sabin PV1-5, PV2-1, and 
PV3-2).The last polio vaccine virus was detected in 2011. 
No poliovirus was found in 2012–2015. Active circulation 
of other enteroviruses was detected in all years. 
CONCLUSIONS. Vaccine-associated polio viruses from 
all polio virus serotypes circulated simultaneously with 
broad-spectrum non-polio enteroviruses until 2008. 
During the two-year period, after introducing inactivated 
polio vaccine in Latvia in 2006, the laboratory detected 
only sporadic polio vaccine-associated viruses but none 
in 2012–2015. Obtained data gives us the possibility to 
characterize the intensity and spectra of polio and non-
polio enteroviruses circulating in Latvia, and to estimate 
and control surveillance of polio virus circulation. 
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Estonia Medical Centre
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OBJECTIVES. The concept of “brain-to-brain loop” for 
laboratory testing was introduced by Lundberg in 1975. 
According to this concept, the loop begins in the brain of 
the physician with the postulation of the clinical question 
and the selection of laboratory tests, followed by sample 
collection and transportation to the laboratory, as well as by 
the measurement of analytes at the laboratory and delivery 
of the result to the physician.  e loop closes in the brain of 
the physician with a decision about patient management. 
Applying the brain-to-brain loop concept, the manage-
ment of porphyrias (P) at our hospital was improved.  e 
aim of our study was to present changes that led to this 
improvement. 
METHODS. We retrospectively analysed changes in 
the process. Prior to 2011, only alfa-aminolevulinic acid 
and koproporphyrin were measured in urine by at-home 
methods. At the beginning of 2011 the P laboratory was 
merged with the toxicology laboratory and we started 
with changes in the handling protocol of P, which included 
standardisation in the preanalytic, analytic and postana-
lytic steps.  e ﬁ rst-line porphyrin tests were broadened by 
urine porphobilinogen and total porphyrins; additionally, 
lead analysis was also added for diﬀ erentiation between 
lead poisoning and P. Collaboration between laboratory 
physicians and experienced clinicians was also encouraged 
to minimise problems caused by communication gaps and 
to improve the quality of patient management.
RESULTS. When prior to the introduction of the changes, 
1612 porphyrins were measured, then after this their 
number was 1236. Among them, regarding prior to and 
after changes, 19% and 5% of the results, respectively, were 
mildly increased and not associated with P, while 1.6% and 
5.4% of the results, respectively, were associated with P. 
CONCLUSION.  e brain-to-brain concept that has been 
applied in our laboratory for diagnosing of P during recent 
10 years has lead to the improvement of the quality of 
patient-centred medical care in this ﬁ eld. 
PP-34. Investigation of porphyrias: 10-year 
experience at the North Estonia Medical Centre
Galina Zemtsovskaja1, Marika Pikta1, Julia Borissova2, 
Küllike Palk2, Ulvi Sorro4, Katrin Gross-Paju4, Vadim Brjalin5, 
Mihhail Zemtsovski5, Katrin Nõukas6, Katrin Eino3, Katrin 
Tammeväli3, Viive Pille2, Olga Lotkova1, Kristi Lepik7, 
Merike Luman2, Margus Viigimaa2, 8 – 1Diagnostic Division, 
Laboratory, North Estonia Medical Centre, Tallinn, Estonia; 
2Internal Medicine Clinic, North Estonia Medical Centre, 
Tallinn, Estonia; 3Psychiatry Clinic, North Estonia Medical 
Centre, Tallinn, Estonia; 4Neurology Clinic, North Estonia 
Medical Centre; 5Internal Medicine Clinic, West Tallinn 
Central Hospital, Tallinn, Estonia; 6Internal Medicine Clinic, 
East Tallinn Central Hospital; 7Hematology Department, 
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Medicine, Tallinn University of Technology, Tallinn, Estonia
E-mail: galina.zemtsovskaja@regionaalhaigla.ee
OBJECTIVES. Porphyrias (P) are the group of disorders caused 
by deﬁ ciency in one of the enzymes in the heme synthesis 
pathway. According to clinical presentation, P are usually 
classiﬁ ed as acute or cutaneous. Acute P is usually clinically 
present with acute neurovisceral crisis, while cutaneous P 
is characterized by skin photosensitivity and lesions.  
Diagnosis of P can be made by combining clinical infor-
mation with laboratory testing. When acute P is suspected, 
it is usually necessary to have three tests for ﬁ rst-line deter-
mination: urinary porphobilinogen, alfa-aminolevulinic 
acid and total porphyrins. In cutaneous presentation, total 
urinary or plasma porphyrins are more appropriate.
In Estonia, there are only two hospitals where the 
ﬁ rst-line biochemical methods are available. One of them 
is North Estonia Medical Centre. Our laboratory receives 
samples for measurement of porphyrins from all hospitals 
of Tallinn, capital of Estonia.
We analysed retrospectively porphyrins test utiliza-
tion, based on the data of the measurements of porphyrins 
performed at our laboratory in 2006–2015.
METHODS. The data for all porphyrin analyses were 
drawn from the LIS database. 
RESULTS.  e laboratory performed 2848 porphyrins 
analyses for 948 patients in 2006–2015.
Most of the patients with suspicion of P had been 
referred by physicians of occupational diseases (660), 
gastroenterologists (159) and neurologists (87), the least 
of the papients had been referred by dermatologists (13), 
nephrologists (12), haematologists (6), surgeons and emer-
gency physicians (5), as well as by psychiatrists (4) and 
cardiologists (2). P was diagnosed either only on the basis 
of clinical symptoms and porphyrin results (13 patients) 
or additional DNA analysis (6 patients). All patients with P 
received appropriate timely treatment. 
CONCLUSION.  e clinical presentation of P is often 
non-speciﬁ c. Our experience in the ﬁ eld of P investigation 
has demonstrated the importance of the impact of ﬁ rst-line 
biochemical testing on diagnosis. 
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PP-35. Application of six sigma for quality 
assurance at the laboratory of North Estonia 
Medical Centre
Monica Tilk, Ella Kuusmets, Ave Lellep – Laboratory, 
North Estonia Medical Centre, Tallinn, Estonia
E-mail: Monica.Tilk@regionaalhaigla.ee
OBJECTIVES. To comply with the requirements of ISO 
15189:2012 we have to constantly assess and monitor the 
laboratory s´ contribution to patient care. Therefore, the 
quality indicators (QI) of the pre-analytical, analytical 
and post-analytical phases are measured. One aspect of 
assuring the quality of laboratory testing is monitoring 
the level of analytical performance of tests. The aim of 
this study was to apply the Six Sigma concept for assess-
ment of laboratory performance. 
METHODS. The QI and the analytical performance of 
the test data (28 immunoassay tests, 35 clinical chemistry 
tests) were registered within a period of one year. The QI 
chosen for monitoring the pre-analytical (6), analytical 
(3) and post-analytical (1) phases were measured by 
calculating defects per million (DPM) and converting 
the measurement results into the Sigma metric. The 
analytical performance of the tests was quantified by 
the Sigma metrics using the equation “Sigma-metric = 
(TEa% - Bias%)/CV%”.
RESULTS. Laborator y per formance in the pre-
analytical phase ranged between 3.5–5.6 Sigma (), in 
the analytical phase between 3.5–4.5  and in the post-
analytical phase 5.3 . Of  the immunoassay tests 71% 
and of the clinical chemistry tests 54% performed higher 
than 6 . Of the immunoassay tests 4% and of the clinical 
chemistry tests 20% performed under 3 . 
CONCLUSIONS. This study shows that the Six Sigma 
concept is an applicable method for assessing and 
improving the quality of our laboratory services. The 
Six-Sigma scale provides a universal benchmark for 
comparing the quality of our laboratory and its analytical 
performance of tests with those of other laboratories. 
PP-36. Actionable mutations in the whole-
genome sequenced gene donors of the 
Estonian Biobank
Neeme Tõnisson1, 2, Tiit Nikopensius1, Karmen Vaiküll1, 
Liis Leitsalu1, Mart Kals1, Peeter Padrik3, Tõnu Esko1, 
4, Andres Metspalu1, 5 – 1Estonian Genome Center, 
University of Tartu, Tartu, Estonia; 2Department of 
Genetics, Tartu University Hospital, Tartu, Estonia; 
3Oncology Clinic, Tartu University Hospital, Tartu, 
Estonia; 4Broad Institute, Cambridge, MA, USA; 5Institute 
of Molecular and Cell Biology, University of Tartu, Tartu, 
Estonia
E–mail: neeme.tonisson@kliinikum.ee
INTRODUCTION. In 2013, the American Col lege of 
Medical Geneticists (ACMG) issued a minimal list of 24 
actionable conditions and 56 related genes that are of 
medical utility and should be reported back if inciden-
tally found mutated in clinical whole genome and whole 
exome sequencing. 
OBJECTIVES AND METHODS. At the Estonian Genome 
Center, we have performed whole genome sequencing 
of over 2200 individuals selected to be a representative 
subset of the Estonian population with approximately 
30x mean coverage. The data is meant to be used for a 
variety of further population and health-related studies. 
As one of the aims of our biobank is to provide feedback 
to the gene donors regarding their health risks, we were 
searching for the sequencing data for known and expected 
pathogenic mutations, starting from the ACMG gene list 
as the first priority.
RESULTS. Based on initial filtering, database and 
literature search, we were able to detect 33 variants 
in 20 genes related to 13 clinical conditions in the 
ACMG list mentioned above. Forty five individuals (2% 
of the sequenced cohort) carried the variants. One of 
the surprises was that 16 individuals with known and 
expected BRCA1 and BRCA2 pathogenic mutations (0.7% 
of total) were detected in the sequencing cohort.
PERSPECTIVES. The sequencing data will be further 
validated and used to set up a health-related feedback 
routine at our biobank, together with required profes-
sional counselling. 
Eesti Arst 2016;95(Supplement 1):1–72 63
POSTER PRESENTATIONS
PP-37. Changes in inflammatory and 
immunological parameters during progression 
of renal cell carcinoma
Ieva Vaivode, Margarita Citoviča, Ludmila Eņģele, Vilnis 
Lietuvietis, Dace Baltiņa, Simona Doniņa – Riga Stradins 
University, Riga East University Hospital, Riga, Latvia
E-mail: ievavvd@gmail.com
AIM. To establish inf lammatory and immunological 
markers that significantly correlate with presence, stage 
and prognosis of RCC.
METHODS. Before treatment, the peripheral blood 
of patients with suspected RCC was tested for C reactive 
protein (CRP), erythrocyte sedimentation rate (ESR), 
lactate dechydrogenase (LDH), white blood cell (WBC), 
neutrophil (Ne), monocyte (Mo), lymphocyte (Ly) platelet 
(PLT) count and Ly subpopulations: CD3+, CD3+CD4+, 
CD3+CD8+, CD38+, CD16+CD56+, CD19+, CD95+ using a 
f low cytometer. The study was launched on 25.11.2013 
with follow up of 158 patients from a single institution 
until 01.12.15.
RESULTS. Nineteen patients had benign tumours, 139 
had RCC, among them 85 with stage I, 9 with stage II, 
12with stage III and 33 with stage IV or with recurrence. 
Between the groups of local and advanced RCC stages there 
was found a statistically significant difference for: WBC 
(p = 0.02), Ne (p = 0.05), PLT (p = 0.001), Mo (p = 0.01), 
CRP (p = 0.001), LDH (p = 0.008), PLT/Ly (p = 0.001), Mo/
Ly (p = 0.019). The only variable that apparently differed 
between the patients with benign and malignant tumours 
was Mo/Ly ratio, although this difference did not reach 
statistical significance (p = 0.057). In 45 patients with 
the advanced disease, a statistically significant difference 
in survival distributions between the groups with lab 
results above or below median values was observed for 
PLT (p = 0.002), CRP (p = 0.01), ESR (p = 0.002), CD8+/
CD19+ (p = 0.023), PLT/Ly (p = 0.049).
CONCLUSIONS. The most significant correlation with 
stage of RCC was proved for PLT, Mo, CRP, ESR, CD19+ and 
PLT/ Ly ratio. A difference in Mo/Ly ratio was observed 
in association with presence of malignancy, which might 
serve as a useful diagnostic marker. The PLT, CRP, ESR, PLT/
Lyand CD8+/CD19+ may predict survival in advanced RCC.
PP-38. Increase of immature granulocytes in 
septic patients within the first 24 hours of 
hospitalisation
Maarit Veski, Jevgeni Rušai, Tiit Salum, Agu Tamm – 
Chair of Laboratory Medicine, University of Tartu, Tartu, 
Estonia
E-mail: mveski@hotmail.com 
BACKGROUND. Studies have shown that the count 
of immature granulocytes (IG) increases in the early 
stages of sepsis. We analysed how many patients who are 
diagnosed with sepsis at hospitalisation have abnormal 
level of IG, and whether this is related to procalcitonin 
(PCT) values, causative bacteria and disease outcome.
MATERIAL AND METHODS.  e study is based on the 
medical records of patients from the Internal Medicine 
Clinic of Tartu University Hospital.  e results of 46 
patients aged 27–91 (mean 70years) were analysed, among 
them 28 with the diagnosis of sepsis and 18 without this 
diagnosis but with infection. In the ﬁ rst group 14/28 were 
men, in the second; 7/18. Six patients died during 30 days 
after hospitalisation and one patient died 2 months later: 
thus there were 7 deaths. We compared the IG and PCT 
values measured within the ﬁ rst 24 hours.  e IG was 
assayed with Sysmex XE-2100 or XE-5000 hematological 
analyser, using ﬂ ow cytometry; PCT was assayed by the 
ECLIA method. An IG count over 0.06 x 109/l, IG% over 
0.6%, and PCT over 2 ng/ml were considered increased. 
In the septic group, blood cultures were gram-negative 
(G-) in 16 cases and gram-positive (G+) in 6 cases; 2 G-/
G+ bacteria were isolated, in 4 cases the pathogen was 
not isolated.  
RESULTS. The IG count was elevated in 13/28 patients 
in the sepsis group and in 4/18 in the infection group; IG% 
was elevated in 10/28 and 2/18, and PCT was elevated, in 
16/28 and 9/18, respectively. The CRP was 4–416 mg/l, < 
10mg/l occurred in only 2 cases; the mean value being 
160 mg/l. There was no correlation between IG and PCT. 
From the blood cultures of patients with an increase in IG, 
7 G- and 4 G+ pathogens were isolated, bacteria were not 
cultivated in 2 cases. The patients who died had shown 
abnormal IG count in 5/7, IG% 3/7 and PCT in 4/7 during 
the first 24 hours. Most of them (5/7) had G- bacteria.  
CONCLUSIONS.  
1. An increase in IG and PTC was found both in septic 
and non- septic patients during the first 24 hours of 
hospitalisation.  
2. An increase in IG was found in patients with both 
G+ and G- infections.  
3. The IG is a well available test which could provide 
useful diagnostic and prognostic information. 
4. This pilot project should be carried on to make 
more detailed conclusions.  
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